US5688666A
(en)
*
|
1988-10-28 |
1997-11-18 |
Genentech, Inc. |
Growth hormone variants with altered binding properties
|
US5534617A
(en)
*
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5350836A
(en)
*
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
US5723286A
(en)
*
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
WO1992009690A2
(en)
*
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
JP3672306B2
(ja)
|
1991-04-10 |
2005-07-20 |
ザ スクリップス リサーチ インスティテュート |
ファージミドを使用するヘテロ二量体受容体ライブラリー
|
ATE196548T1
(de)
|
1991-05-10 |
2000-10-15 |
Genentech Inc |
Auswählen von agonisten und antagonisten von liganden
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US5871907A
(en)
*
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
DE4122599C2
(de)
*
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
DK1024191T3
(da)
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6297026B1
(en)
|
1993-07-26 |
2001-10-02 |
Cor Therapeutics Inc. |
Nucleic acids encoding the C140 receptor
|
EP0741783B1
(de)
|
1993-12-30 |
2009-03-18 |
President And Fellows Of Harvard College |
"hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
|
US6406855B1
(en)
|
1994-02-17 |
2002-06-18 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US5837458A
(en)
*
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6335319B1
(en)
*
|
1994-11-15 |
2002-01-01 |
Metabolic Pharmaceuticals, Inc. |
Treatment of obesity
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6475806B1
(en)
|
1995-06-07 |
2002-11-05 |
Praecis Pharmaceuticals, Inc. |
Anchor libraries and identification of peptide binding sequences
|
EP1568771A3
(de)
*
|
1995-09-21 |
2006-05-17 |
Genentech, Inc. |
Varianten des mensclichen Wachstumshormons
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
PT859959E
(pt)
*
|
1995-11-10 |
2003-12-31 |
Elan Corp Plc |
Peptidos que aumentam o transporte atraves dos tecidos e metodos para a sua identificacao e utilizacao
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
WO1997035194A2
(en)
*
|
1996-03-21 |
1997-09-25 |
President And Fellows Of Harvard College |
Enantiomeric screening process, and compositions therefor
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6361938B1
(en)
|
1996-11-08 |
2002-03-26 |
Elan Corporation, Plc |
Peptides which enhance transport across tissues and methods of identifying and using the same
|
US20070185032A1
(en)
*
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6497874B1
(en)
|
1997-02-05 |
2002-12-24 |
Maardh Sven |
Recombinant phages
|
ATE353964T1
(de)
|
1997-04-16 |
2007-03-15 |
Millennium Pharm Inc |
Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
|
US6306826B1
(en)
|
1997-06-04 |
2001-10-23 |
The Regents Of The University Of California |
Treatment of heart failure with growth hormone
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
*
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US6639050B1
(en)
|
1997-07-21 |
2003-10-28 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
US7378506B2
(en)
|
1997-07-21 |
2008-05-27 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
CA2297070A1
(en)
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
GB2375765B
(en)
*
|
1997-11-14 |
2003-02-26 |
Kymed Gb Ltd |
Tagged growth hormone molecules
|
GB9723955D0
(en)
|
1997-11-14 |
1998-01-07 |
Generic Biolog Limited |
Improvements in or relating to detection of molecules in samples
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
EP1481990B1
(de)
|
1997-11-21 |
2007-06-06 |
Genentech, Inc. |
Mit A33 verwandte Antigene und deren pharmazeutische Verwendungen
|
EP1093457B8
(de)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US7056517B2
(en)
|
1998-04-13 |
2006-06-06 |
The Forsyth Institute |
Glucosyltransferase immunogens
|
US7163682B2
(en)
|
1998-04-13 |
2007-01-16 |
The Forsyth Institute |
Glucan binding protein and glucosyltransferase immunogens
|
JP2002522029A
(ja)
*
|
1998-07-27 |
2002-07-23 |
ジェネンテック・インコーポレーテッド |
コートタンパク質の改変によるファージ提示における改良した形質転換効率
|
US6387888B1
(en)
*
|
1998-09-30 |
2002-05-14 |
American Foundation For Biological Research, Inc. |
Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
|
US6485972B1
(en)
|
1998-10-15 |
2002-11-26 |
President And Fellows Of Harvard College |
WNT signalling in reproductive organs
|
US6420110B1
(en)
|
1998-10-19 |
2002-07-16 |
Gpc Biotech, Inc. |
Methods and reagents for isolating biologically active peptides
|
WO2000024415A2
(en)
*
|
1998-10-28 |
2000-05-04 |
Cornell Research Foundation, Inc. |
Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
US6696063B1
(en)
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
US20030194800A1
(en)
*
|
2001-08-31 |
2003-10-16 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
AU2596600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Modified hiv env polypeptides
|
US6602705B1
(en)
*
|
1998-12-31 |
2003-08-05 |
Chiron Corporation |
Expression of HIV polypeptides and production of virus-like particles
|
WO2000039304A2
(en)
*
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
JP3971108B2
(ja)
*
|
1999-01-06 |
2007-09-05 |
ジェネンテック・インコーポレーテッド |
インシュリン様成長因子(igf)i突然変異体
|
AU762047B2
(en)
*
|
1999-01-06 |
2003-06-19 |
Genentech Inc. |
Insulin-like growth factor (IGF) I mutant variants
|
AU3382800A
(en)
|
1999-02-26 |
2000-09-14 |
Millennium Pharmaceuticals, Inc. |
Secreted proteins and uses thereof
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
EP1119368A2
(de)
|
1999-03-03 |
2001-08-01 |
Biogen, Inc. |
Verfahren zür modulierung des fettstoffwechsels und lagerung
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
PL218748B1
(pl)
|
1999-03-25 |
2015-01-30 |
Abbott Gmbh & Co Kg |
Wyizolowane przeciwciało ludzkie lub jego część wiążąca antygen, zawierająca je kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiej IL-12 in vitro, zastosowanie przeciwciała lub jego części wiążącej antygen, sposób wykrywania ludzkiej IL-12, wyizolowana cząsteczka kwasu nukleinowego, zrekombinowany wektor ekspresyjny, komórka gospodarz oraz sposób syntetyzowania ludzkiego przeciwciała lub jego części wiążącej antygen
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
WO2000058521A2
(en)
*
|
1999-03-31 |
2000-10-05 |
Rosetta Inpharmatics, Inc. |
Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US7270969B2
(en)
*
|
1999-05-05 |
2007-09-18 |
Phylogica Limited |
Methods of constructing and screening diverse expression libraries
|
DE60044514D1
(de)
*
|
1999-05-05 |
2010-07-15 |
Phylogica Ltd |
Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielvältigen Genfragmenten
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
ATE296350T1
(de)
*
|
1999-06-14 |
2005-06-15 |
Genentech Inc |
Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage
|
US20030166003A1
(en)
*
|
1999-06-14 |
2003-09-04 |
Cochran Andrea G. |
Structured peptide scaffold for displaying turn libraries on phage
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
PT1144607E
(pt)
|
1999-07-20 |
2009-04-22 |
Morphosys Ag |
Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
|
CA2383456C
(en)
|
1999-08-23 |
2016-06-07 |
Clive Wood |
Pd-1, a receptor for b7-4, and uses therefor
|
DE19943743C2
(de)
*
|
1999-09-03 |
2002-02-07 |
Jerini Biotools Gmbh |
Verfahren zur Identifizierung von Bindungspartnern mit positions-spezifischen Arrays
|
MXPA02003897A
(es)
|
1999-10-20 |
2002-12-13 |
Genentech Inc |
Modulacion de la diferenciacion de celulas t para el tratamiento de enfermedades mediadas por las celulas t auxiliares.
|
US20060073509A1
(en)
*
|
1999-11-18 |
2006-04-06 |
Michael Kilpatrick |
Method for detecting and quantitating multiple subcellular components
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
IL149809A0
(en)
*
|
1999-12-15 |
2002-11-10 |
Genentech Inc |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
US20020004247A1
(en)
*
|
1999-12-23 |
2002-01-10 |
Genentech, Inc. |
Assay method
|
ATE361934T1
(de)
|
1999-12-30 |
2007-06-15 |
Harvard College |
Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
|
WO2002043660A2
(en)
|
2000-11-28 |
2002-06-06 |
Mediummune, Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
EP2360184A3
(de)
|
2000-02-10 |
2011-11-16 |
Abbott Laboratories |
Antikörper zum Binden von humanem Interleukin-18 und Herstellungs- und Verwendungsverfahren
|
US6436677B1
(en)
|
2000-03-02 |
2002-08-20 |
Promega Corporation |
Method of reverse transcription
|
US6632645B1
(en)
|
2000-03-02 |
2003-10-14 |
Promega Corporation |
Thermophilic DNA polymerases from Thermoactinomyces vulgaris
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
WO2001077342A1
(en)
|
2000-04-11 |
2001-10-18 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU2001264563A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
CA2406236C
(en)
*
|
2000-04-17 |
2013-02-19 |
Dyax Corp. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
WO2001081375A2
(en)
*
|
2000-04-24 |
2001-11-01 |
Yale University |
Dna & protein binding miniature proteins
|
US7495070B2
(en)
*
|
2000-04-24 |
2009-02-24 |
Yale University |
Protein binding miniature proteins
|
EP1282437B1
(de)
*
|
2000-05-16 |
2008-03-19 |
Genentech, Inc. |
Behandlung von knorpelerkrankungen
|
US6573370B1
(en)
|
2000-05-19 |
2003-06-03 |
Regents Of The University Of Michigan |
PON3 and uses thereof
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
ES2343351T3
(es)
|
2000-06-08 |
2010-07-29 |
Immune Disease Institute, Inc. |
Procedimientos y composiciones para inhibir la lesion por reperfusion mediada por inmunoglobulina.
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
KR101287395B1
(ko)
|
2000-06-16 |
2014-11-04 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 BLyS에 결합하는 항체
|
WO2002000617A2
(en)
*
|
2000-06-28 |
2002-01-03 |
Bristol-Myers Squibb Company |
Selective androgen receptor modulators and methods for their identification, design and use
|
CA2413857C
(en)
|
2000-06-28 |
2010-04-27 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
ATE420958T1
(de)
|
2000-06-29 |
2009-01-15 |
Abbott Lab |
Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
|
US7176037B2
(en)
*
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US6951947B2
(en)
*
|
2000-07-13 |
2005-10-04 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
EP1301532B1
(de)
|
2000-07-14 |
2011-02-02 |
CropDesign N.V. |
Inhibitoren für cyclin-dependent-kinase von pflanzen
|
US6878861B2
(en)
|
2000-07-21 |
2005-04-12 |
Washington State University Research Foundation |
Acyl coenzyme A thioesterases
|
EP2014303A2
(de)
|
2000-07-27 |
2009-01-14 |
Genentech, Inc. |
APO-2L-Rezeptorantagonisten und CPT-11-Synergismus
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
EP1309312A2
(de)
*
|
2000-08-07 |
2003-05-14 |
Inhale Therapeutic Systems, Inc. |
Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
WO2002022154A2
(en)
*
|
2000-09-13 |
2002-03-21 |
Praecis Pharmaceuticals Incorporated |
Pharmaceutical compositions for sustained drug delivery
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
CA2420475A1
(en)
|
2000-09-26 |
2002-04-04 |
Genentech, Inc. |
Ige receptor antagonists
|
US7393532B1
(en)
|
2000-10-18 |
2008-07-01 |
Genentech, Inc. |
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US6841359B2
(en)
*
|
2000-10-31 |
2005-01-11 |
The General Hospital Corporation |
Streptavidin-binding peptides and uses thereof
|
CA2427820A1
(en)
|
2000-11-01 |
2002-06-13 |
Elusys Therapeutics, Inc. |
Method of producing biospecific molecules by protein trans-splicing
|
AU3650302A
(en)
|
2000-11-28 |
2002-06-11 |
Wyeth Corp |
Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
BR0115715A
(pt)
|
2000-11-28 |
2004-02-03 |
Wyeth Corp |
Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
EP1498429A3
(de)
*
|
2000-12-05 |
2005-08-03 |
Alexion Pharmaceuticals, Inc. |
Rationell entworfene Antikörper
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
AU2002246632B2
(en)
*
|
2000-12-08 |
2007-04-05 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
EP2341060B1
(de)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
AU2002249854B2
(en)
|
2000-12-18 |
2007-09-20 |
Dyax Corp. |
Focused libraries of genetic packages
|
WO2002051870A2
(en)
*
|
2000-12-22 |
2002-07-04 |
GRAD, Carole Legal Representative of KAPLAN, Howard |
Phage display libraries of human vh fragments
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
AU2002250032B2
(en)
|
2001-02-09 |
2008-06-05 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
EP2316276A3
(de)
|
2001-02-23 |
2011-08-03 |
DSM IP Assets B.V. |
Genes qui codant pour l'enzymes proteolytiques derivees de aspargilli
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
US20030165873A1
(en)
|
2001-03-02 |
2003-09-04 |
Come Jon H. |
Three hybrid assay system
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
EP1379125A4
(de)
|
2001-03-22 |
2004-12-08 |
Abbott Gmbh & Co Kg |
Transgene tiere, die für interessierende gene spezifische antikörper exprimieren, sowie deren verwendung
|
CA2442066C
(en)
|
2001-04-02 |
2005-11-01 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
KR20030093316A
(ko)
|
2001-04-13 |
2003-12-06 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
혈관 내피 성장 인자 2
|
EP2258842A1
(de)
|
2001-04-16 |
2010-12-08 |
Wyeth Holdings Corporation |
Polypeptidantigene codierende offene Leseraster aus Streptococcus Pneumoniae und Verwendungen davon
|
US6914123B2
(en)
*
|
2001-04-17 |
2005-07-05 |
Genentech, Inc. |
Hairpin peptides with a novel structural motif and methods relating thereto
|
US7244853B2
(en)
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
CN100594935C
(zh)
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
WO2002098280A2
(en)
*
|
2001-06-04 |
2002-12-12 |
Ikonisys Inc. |
Method for detecting infectious agents using computer controlled automated image analysis
|
US20030113714A1
(en)
*
|
2001-09-28 |
2003-06-19 |
Belcher Angela M. |
Biological control of nanoparticles
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20050164515A9
(en)
*
|
2001-06-05 |
2005-07-28 |
Belcher Angela M. |
Biological control of nanoparticle nucleation, shape and crystal phase
|
US20030148380A1
(en)
*
|
2001-06-05 |
2003-08-07 |
Belcher Angela M. |
Molecular recognition of materials
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
EP2270184A3
(de)
|
2001-06-22 |
2012-04-11 |
Pioneer Hi-Bred International, Inc. |
Defensinpolynucleotide und Verfahren zu ihrer Verwendung
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
EP2280074A3
(de)
*
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
DE10135039C1
(de)
*
|
2001-07-18 |
2003-03-13 |
Nemod Immuntherapie Ag |
Verfahren zur Isolierung großer Varianzen spezifischer Moleküle für ein Zielmolekül aus Phagemid-Gen-Bibliotheken
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
KR100458083B1
(ko)
*
|
2001-08-29 |
2004-11-18 |
주식회사 아이지세라피 |
파아지 디스플레이 라이브러리로부터 특정 이종 단백질의효율적인 분리를 위한 개선된 헬퍼 파아지 시스템
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP1425040A2
(de)
*
|
2001-09-14 |
2004-06-09 |
Cytos Biotechnology AG |
Steigerung der durch virusähnliche partikel hervorgerufenen immunantwort durch in-vivo aktivierung von antigen-präsentierenden zellen
|
EP2174953A1
(de)
|
2001-09-18 |
2010-04-14 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US20030073104A1
(en)
*
|
2001-10-02 |
2003-04-17 |
Belcher Angela M. |
Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
EP1458754B1
(de)
|
2001-12-18 |
2009-12-09 |
Endocube SAS |
Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US7087418B2
(en)
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
EP1997829A1
(de)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2005523888A
(ja)
*
|
2002-01-03 |
2005-08-11 |
ザ スクリプス リサーチ インスティテュート |
癌関連エピトープ
|
JP2005523688A
(ja)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
EP1489968B1
(de)
*
|
2002-03-01 |
2009-02-18 |
Siemens Healthcare Diagnostics Inc. |
Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
|
ES2329565T3
(es)
|
2002-03-01 |
2009-11-27 |
Siemens Healthcare Diagnostics Inc. |
Pruebas para monitorear pacientes con cancer, basadas en los niveles de analito de dominio extracelular (ecd) del factor receptor del crecimiento epidermico (egfr),solo o en combinacion con otros analitos,en muestras de fluidos corporales.
|
JP2005531511A
(ja)
|
2002-03-07 |
2005-10-20 |
ザ フォーシス インスティチュート |
グルカン結合タンパク質の免疫原性
|
EP1497445A2
(de)
*
|
2002-04-01 |
2005-01-19 |
Human Genome Sciences, Inc. |
Spezifisch an gmad bindende antikörper
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7745192B2
(en)
|
2002-04-03 |
2010-06-29 |
Venomics Pty Limited |
Prothrombin activating protein
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
WO2003097825A2
(en)
|
2002-05-21 |
2003-11-27 |
Dsm Ip Assets B.V. |
Novel phospholipases and uses thereof
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
WO2003102157A2
(en)
*
|
2002-06-03 |
2003-12-11 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CN100418981C
(zh)
*
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
WO2003106640A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Case Western Reserve University |
Cell targeting methods and compositions
|
US7667099B2
(en)
|
2002-06-20 |
2010-02-23 |
Board Of Trustees Of Michigan State University |
Plastid division and related genes and proteins, and methods of use
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
PL213925B1
(pl)
|
2002-07-19 |
2013-05-31 |
Abbott Biotech Ltd |
Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
KR20050062525A
(ko)
|
2002-08-10 |
2005-06-23 |
예일 유니버시티 |
Nogo 수용체 길항제
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
MXPA05001978A
(es)
|
2002-08-19 |
2005-04-28 |
Dsm Ip Assets Bv |
Nuevas lipasas y usos de las mismas.
|
ATE519862T1
(de)
|
2002-08-20 |
2011-08-15 |
Millennium Pharm Inc |
Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
|
DE10238846A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Nemod Immuntherapie Ag |
Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
|
US7455989B2
(en)
|
2002-08-20 |
2008-11-25 |
Yeda Research And Development Co. Ltd. |
AKAP84 and its use for visualization of biological structures
|
AU2003243398A1
(en)
*
|
2002-08-29 |
2004-03-19 |
Genentech, Inc. |
Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
|
CN1694715B
(zh)
|
2002-09-04 |
2010-12-01 |
路易斯维尔大学研究基金会 |
β葡聚糖和抗体在制备治疗癌性的药物中的用途
|
CA2498319A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
US20050064508A1
(en)
*
|
2003-09-22 |
2005-03-24 |
Semzyme |
Peptide mediated synthesis of metallic and magnetic materials
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
WO2004032870A2
(en)
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
EP1633786A4
(de)
*
|
2002-10-09 |
2007-07-25 |
Rinat Neuroscience Corp |
Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
|
US7429382B2
(en)
|
2002-10-16 |
2008-09-30 |
Corixa Corporation |
Antibodies that bind cell-associated CA 125/O772P and methods of use thereof
|
ES2347239T3
(es)
*
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
US7056702B2
(en)
*
|
2002-12-16 |
2006-06-06 |
Kimberly Clark Co |
Detecting lipocalin
|
US20050089521A1
(en)
*
|
2002-12-23 |
2005-04-28 |
Shelton David L. |
Methods for treating taxol-induced sensory neuropathy
|
WO2004058968A1
(de)
*
|
2002-12-23 |
2004-07-15 |
Apalexo Biotechnologie Gmbh |
Reinigung rekombinanter filamentöser bakteriophagen mittels affinitätschromatografie zur erhöhung der immunogenität und wirkung von phagenimpfstoffen
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
ES2382918T3
(es)
|
2002-12-24 |
2012-06-14 |
Rinat Neuroscience Corp. |
Anticuerpos anti-NGF y procedimientos que usan los mismos
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
DE602004031589D1
(de)
|
2003-01-07 |
2011-04-14 |
Dyax Corp |
Kunitz-domäne-bibliothek
|
US20050079574A1
(en)
*
|
2003-01-16 |
2005-04-14 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004065551A2
(en)
*
|
2003-01-21 |
2004-08-05 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
US7429472B2
(en)
|
2003-01-31 |
2008-09-30 |
Promega Corporation |
Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
|
US7238842B2
(en)
|
2003-01-31 |
2007-07-03 |
Promega Corporation |
Covalent tethering of functional groups to proteins
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
SI2000481T1
(sl)
*
|
2003-02-01 |
2016-08-31 |
Tanox, Inc. |
Anti-humana protitelesa IgE z visoko afiniteto
|
EP1594441B1
(de)
*
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
SI1606409T1
(sl)
|
2003-03-19 |
2011-01-31 |
Biogen Idec Inc |
Vezavni protein receptorja Nogo
|
JP2006520806A
(ja)
*
|
2003-03-20 |
2006-09-14 |
ライナット ニューロサイエンス コーポレイション |
タキソール誘導性腸障害を処置する方法
|
US7294701B2
(en)
*
|
2003-04-02 |
2007-11-13 |
Technion Research & Development Foundation Ltd. |
Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
|
ES2391087T3
(es)
|
2003-04-11 |
2012-11-21 |
Medimmune, Llc |
Anticuerpos de IL-9 recombinantes y usos de los mismos
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
BRPI0411200A
(pt)
|
2003-05-30 |
2006-07-18 |
Genentech Inc |
método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer
|
EP1639009B1
(de)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab-bibliothek zur herstellung von einer mischung von antikörpern
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
CA2528343A1
(en)
|
2003-06-06 |
2005-01-06 |
Genentech, Inc. |
Modulating the interaction between hgf beta chain and c-met
|
JP2007516693A
(ja)
*
|
2003-06-09 |
2007-06-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
癌の治療および診断のための組成物および方法
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
EP2784084B2
(de)
|
2003-07-08 |
2023-10-04 |
Novartis Pharma AG |
Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen
|
WO2005010163A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
|
EP1644408A1
(de)
*
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella-antigen zur immuntherapie von kokzidiose
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
JP2007504244A
(ja)
*
|
2003-09-05 |
2007-03-01 |
ザ スクリプス リサーチ インスティテュート |
アテローム硬化症および/または心血管性疾患の処置および予防のためのコレステロールのオゾン化産物
|
US20050085556A1
(en)
*
|
2003-09-05 |
2005-04-21 |
Paul Wentworth |
Detection of cholesterol ozonation products
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CA2761987A1
(en)
|
2003-10-07 |
2005-04-21 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
US7576052B2
(en)
|
2003-10-17 |
2009-08-18 |
Joslin Diabetes Center, Inc. |
Methods and compositions for modulating adipocyte function
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
ES2493016T3
(es)
|
2003-11-17 |
2014-09-11 |
Genentech, Inc. |
Composiciones que comprenden anticuerpos contra CD79b conjugados a un agente inhibidor del crecimiento o un agente citotóxico y procedimientos para el tratamiento de tumores de origen hematopoyético
|
PT1983000E
(pt)
|
2003-11-21 |
2015-12-30 |
Ucb Biopharma Sprl |
Método para o tratamento de esclerose múltipla através da inibição da atividade de il-17
|
CA2548180C
(en)
*
|
2003-12-04 |
2014-02-04 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
AU2004298483A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
GB0329825D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
EP2402756A3
(de)
*
|
2003-12-23 |
2012-02-22 |
Rinat Neuroscience Corp. |
Agonistische anti-trkC-AntiKörper und Verfahren zur Verwendung davon
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
NZ548702A
(en)
|
2004-01-09 |
2009-06-26 |
Pfizer |
Antibodies to MAdCAM
|
US20060148680A1
(en)
|
2004-01-14 |
2006-07-06 |
Kieliszewski Marcia J |
Glycoproteins produced in plants and methods of their use
|
EP1761561B1
(de)
|
2004-01-20 |
2015-08-26 |
KaloBios Pharmaceuticals, Inc. |
Antikörper-spezifitätstransfer mit minimal essentiell bindenden determinanten
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー.ヴィー. |
結合タンパク質の混合物
|
EP2368579A1
(de)
|
2004-01-21 |
2011-09-28 |
Novo Nordisk Health Care AG |
Tranglutaminase vermittelte konjugation von peptiden.
|
US20060014211A1
(en)
|
2004-01-21 |
2006-01-19 |
Fujirebio Diagnostics, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
|
EP1718664A4
(de)
|
2004-02-02 |
2008-08-13 |
Ambrx Inc |
Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
|
CA2554779A1
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
AU2005214382B2
(en)
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
DE602005026260D1
(de)
|
2004-03-01 |
2011-03-24 |
Immune Disease Inst Inc |
Natürliche igm-antikörper und inhibitoren davon
|
EP1735453A2
(de)
*
|
2004-03-12 |
2006-12-27 |
The Scripps Research Institute |
Fluoreszenz-signale abgebende biosensor-moleküle und farbstoffe in lebenden zellen zum nachweis und zur quantifizierung von protein aktivitäten
|
EP2293069A3
(de)
|
2004-03-24 |
2011-09-21 |
Tripath Imaging, Inc. |
Verfahren und Zusammensetzungen zum Nachweis von zervikalen Erkrankungen
|
US7973139B2
(en)
*
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
KR101245983B1
(ko)
|
2004-03-31 |
2013-06-28 |
제넨테크, 인크. |
인간화 항-tgf-베타 항체
|
CA2562024C
(en)
*
|
2004-04-07 |
2014-05-27 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2955027A1
(en)
|
2004-04-15 |
2005-11-10 |
University Of Florida Research Foundation, Inc. |
Neural proteins as biomarkers for nervous system injury and other neural disorders
|
CA2558963A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Genentech, Inc. |
Omi pdz modulators
|
WO2005110015A2
(en)
|
2004-04-19 |
2005-11-24 |
Ohio University |
Cross-linkable glycoproteins and methods of making the same
|
ES2442386T3
(es)
|
2004-04-23 |
2014-02-11 |
Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr |
Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
|
AU2005250369A1
(en)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
|
EP1602928A1
(de)
*
|
2004-06-01 |
2005-12-07 |
Universiteit Maastricht |
Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen
|
US20110218118A1
(en)
*
|
2004-06-03 |
2011-09-08 |
Phylogica Limited |
Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
|
CN102453763A
(zh)
|
2004-06-03 |
2012-05-16 |
阿什洛米克斯控股有限公司 |
诊断应激的药物和方法
|
US7604947B2
(en)
*
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
US7632924B2
(en)
*
|
2004-06-18 |
2009-12-15 |
Ambrx, Inc. |
Antigen-binding polypeptides and their uses
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
EP1776136B1
(de)
|
2004-06-24 |
2012-10-03 |
Biogen Idec MA Inc. |
Behandlung von entmyelinisierenden erkrankungen
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
JP2008506681A
(ja)
|
2004-07-16 |
2008-03-06 |
ファイザー・プロダクツ・インク |
抗igf−1r抗体を用いる非血液性の悪性腫瘍の併用療法
|
EP2361931B1
(de)
*
|
2004-07-20 |
2017-12-06 |
Genentech, Inc. |
Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP1771573A4
(de)
*
|
2004-07-21 |
2009-02-18 |
Ambrx Inc |
Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
US7425436B2
(en)
|
2004-07-30 |
2008-09-16 |
Promega Corporation |
Covalent tethering of functional groups to proteins and substrates therefor
|
US20070087400A1
(en)
*
|
2004-07-30 |
2007-04-19 |
Aldis Darzins |
Covalent tethering of functional groups to proteins and substrates therefor
|
SG190665A1
(en)
|
2004-07-30 |
2013-06-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
HUE058817T2
(hu)
*
|
2004-09-03 |
2022-09-28 |
Genentech Inc |
Humanizált anti-béta7 antagonisták és alkalmazásaik
|
EP1793850A4
(de)
|
2004-09-21 |
2010-06-30 |
Medimmune Inc |
Antikörper gegen und verfahren zur herstellung von impfstoffen gegen das respiratory syncytial virus
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
PT1802334E
(pt)
|
2004-10-21 |
2012-11-28 |
Genentech Inc |
Método para tratamento de doenças neovasculares intraoculares
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
JP2008524242A
(ja)
*
|
2004-12-16 |
2008-07-10 |
ジェネンテック・インコーポレーテッド |
自己免疫障害を治療する方法
|
US8080391B2
(en)
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
SG160437A1
(en)
|
2004-12-22 |
2010-04-29 |
Ambrx Inc |
Modified human growth hormone
|
NZ555386A
(en)
*
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
CA2592390A1
(en)
|
2004-12-22 |
2006-06-29 |
Genentech, Inc. |
Methods for producing soluble multi-membrane-spanning proteins
|
CN101087875B
(zh)
*
|
2004-12-22 |
2012-08-22 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
JP4937138B2
(ja)
|
2005-01-05 |
2012-05-23 |
エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
|
AU2006203889A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
CRIPTO binding molecules
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
WO2006086242A2
(en)
|
2005-02-07 |
2006-08-17 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
PT1853718E
(pt)
|
2005-02-15 |
2015-11-12 |
Univ Duke |
Anticorpos anti-cd19 e usos em oncologia
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
EP1858545A2
(de)
*
|
2005-03-04 |
2007-11-28 |
Curedm Inc. |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
EP1861126A4
(de)
|
2005-03-22 |
2009-11-18 |
Harvard College |
Behandlung von proteinabbaustörungen
|
EP3312196B1
(de)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antikörper gegen cd38 zur behandlung von multiplem myelom
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
EP1871418B1
(de)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
|
US7807159B2
(en)
|
2005-04-25 |
2010-10-05 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
AR054260A1
(es)
*
|
2005-04-26 |
2007-06-13 |
Rinat Neuroscience Corp |
Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
|
UA95775C2
(uk)
|
2005-04-26 |
2011-09-12 |
Пфайзер Инк. |
Антитіло, яке специфічно зв'язується з р-кадгерином
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
MY148086A
(en)
*
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
PL1899364T3
(pl)
|
2005-05-17 |
2020-08-24 |
University Of Connecticut |
Kompozycje i sposoby immunomodulacji w organizmie
|
WO2006128083A2
(en)
|
2005-05-25 |
2006-11-30 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
LT2460831T
(lt)
|
2005-05-27 |
2016-12-12 |
Biogen Ma Inc. |
Tweak rišantys antikūnai
|
CN101247821B
(zh)
*
|
2005-06-03 |
2013-01-23 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
EP1871163A2
(de)
|
2005-06-06 |
2008-01-02 |
Genentech, Inc. |
Transgene tiermodelle und deren verwendung zur gencharakterisierung
|
US20070099209A1
(en)
*
|
2005-06-13 |
2007-05-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
EA015148B1
(ru)
|
2005-06-17 |
2011-06-30 |
Элан Фарма Интернэшнл Лимитед |
СПОСОБЫ ОЧИСТКИ Aβ-СВЯЗЫВАЮЩЕГО БЕЛКА, СОДЕРЖАЩЕГО ОБЛАСТЬ FC
|
EP1893647A2
(de)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
|
KR20130080058A
(ko)
|
2005-06-30 |
2013-07-11 |
아보트 러보러터리즈 |
Il-12/p40 결합 단백질
|
AU2006265002B2
(en)
|
2005-06-30 |
2012-09-20 |
Centocor, Inc. |
Anti-IL-23 antibodies, compositions, methods and uses
|
EP1910565A4
(de)
|
2005-07-07 |
2009-10-28 |
Athlomics Pty Ltd |
Polynukleotidmarkergene und deren expression zur diagnose von endotoxämie
|
EP2478917A1
(de)
|
2005-07-08 |
2012-07-25 |
Biogen Idec MA Inc. |
Sp35-Antikörper und Verwendungen dafür
|
EP1904652A2
(de)
*
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
|
KR20080039929A
(ko)
|
2005-07-22 |
2008-05-07 |
와이스 테라퓨틱스 가부시키가이샤 |
항-cd26 항체 및 이들의 사용 방법
|
JP5645361B2
(ja)
|
2005-08-02 |
2014-12-24 |
エクスバイオテク インコーポレーティッド |
IL−1α自己抗体を用いた血管障害の診断、処置、および予防
|
WO2007014433A1
(en)
|
2005-08-03 |
2007-02-08 |
Grains Research & Development Corporation |
Polysaccharide synthases
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
CN101273140B
(zh)
|
2005-08-18 |
2013-01-16 |
Ambrx公司 |
tRNA组合物和其用途
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
EP2500356A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
EP2500352A1
(de)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
CN107056943B
(zh)
|
2005-09-07 |
2021-06-08 |
安进弗里蒙特公司 |
活化素受体样激酶-1的人单克隆抗体
|
ATE546160T1
(de)
*
|
2005-09-14 |
2012-03-15 |
Ucb Pharma Sa |
Antikörper-kammpolymer-konjugat
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
KR101176830B1
(ko)
|
2005-10-17 |
2012-08-27 |
주식회사 아이지세라피 |
신규한 파아지 디스플레이 방법
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
WO2007050793A2
(en)
|
2005-10-25 |
2007-05-03 |
The Johns Hopkins University |
Methods and compositions for the treatment of marfan syndrome and associated disorders
|
EP1945754B1
(de)
*
|
2005-10-31 |
2014-07-23 |
The Regents Of The University Of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
|
PL1978993T3
(pl)
|
2005-10-31 |
2017-07-31 |
Oncomed Pharmaceuticals, Inc. |
Kompozycje i sposoby leczenia raka oparte na ludzkich receptorach FZD
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
US7919264B2
(en)
|
2005-11-01 |
2011-04-05 |
Abbott Biotechnology Ltd. |
Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
|
US20090246189A1
(en)
|
2005-11-04 |
2009-10-01 |
Biogen Idec Ma Inc. And Mclean Hospital |
Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
|
UA94922C2
(ru)
|
2005-11-07 |
2011-06-25 |
Зе Скріпс Рісьорч Інстітьют |
Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
NZ567234A
(en)
*
|
2005-11-08 |
2011-09-30 |
Ambrx Inc |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
ATE547709T1
(de)
|
2005-11-14 |
2012-03-15 |
Metamol Theranostics Llc |
Tumorinvasionsfördernde peptidsequenz
|
LT2380592T
(lt)
|
2005-11-14 |
2018-05-10 |
Teva Pharmaceuticals International Gmbh |
Antagonistinis antikūnas, nukreiptas prieš su kalcitonino genu susijusį peptidą
|
DK2339014T3
(en)
*
|
2005-11-16 |
2015-07-20 |
Ambrx Inc |
Methods and compositions comprising non-natural amino acids
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
PT1963369E
(pt)
|
2005-11-28 |
2013-05-28 |
Zymogenetics Inc |
Antagonistas de il-21
|
AU2006350038B2
(en)
|
2005-11-30 |
2011-09-15 |
Massachusetts Institute Of Technology |
Pathogen detection biosensor
|
SG10201706600VA
(en)
|
2005-11-30 |
2017-09-28 |
Abbvie Inc |
Monoclonal antibodies and uses thereof
|
PT1954718E
(pt)
|
2005-11-30 |
2014-12-16 |
Abbvie Inc |
Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
|
US20090175872A1
(en)
|
2005-12-02 |
2009-07-09 |
Biogen Idec Ma Inc. |
Treatment of Conditions Involving Demyelination
|
EP1973951A2
(de)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Bindende polypeptide mit eingeschränkten diversitätssequenzen
|
RU2470941C2
(ru)
*
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
EA018044B1
(ru)
|
2005-12-09 |
2013-05-30 |
Юсб Фарма С.А. |
Антитело, специфичное в отношении интерлейкина-6 (ил-6) человека
|
ES2529065T3
(es)
*
|
2005-12-14 |
2015-02-16 |
Ambrx, Inc. |
Composiciones que contienen, procedimientos que implican y usos de aminoácidos no naturales y polipéptidos
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
KR101538521B1
(ko)
|
2005-12-15 |
2015-07-22 |
제넨테크, 인크. |
폴리유비퀴틴 표적화를 위한 방법 및 조성물
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
BRPI0706840A2
(pt)
|
2006-01-05 |
2011-04-05 |
Genentech Inc |
anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
|
NZ599035A
(en)
*
|
2006-01-12 |
2013-12-20 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
EP1981902B1
(de)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo-rezeptorantagonisten
|
CN101410715A
(zh)
|
2006-01-27 |
2009-04-15 |
三路影像公司 |
鉴定患卵巢癌的可能性增加的患者的方法及其组合物
|
US20080038761A1
(en)
*
|
2006-01-30 |
2008-02-14 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
EA017417B1
(ru)
|
2006-02-01 |
2012-12-28 |
Сефалон Астралия Пти Лтд. |
КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
|
WO2008091349A1
(en)
|
2006-02-14 |
2008-07-31 |
The President And Fellows Of Harvard College |
Bifunctional histone deacetylase inhibitors
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
JP5576610B2
(ja)
*
|
2006-02-20 |
2014-08-20 |
フィロジカ リミテッド |
ペプチド構造のライブラリーの構築およびスクリーニング方法
|
EP1998785A4
(de)
*
|
2006-02-21 |
2009-06-17 |
Univ Michigan |
Krebsbehandlung mithilfe eines hedgehog-signalisierungspfades
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
WO2007100640A2
(en)
*
|
2006-02-21 |
2007-09-07 |
The Regents Of The University Of Michigan |
Growth hormone receptor antagonist cancer treatment
|
WO2007100711A2
(en)
*
|
2006-02-24 |
2007-09-07 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
EP2666472A3
(de)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
|
EP2666479A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
WO2007121147A2
(en)
|
2006-04-10 |
2007-10-25 |
Genentech, Inc. |
Disheveled pdz modulators
|
EP2010662A2
(de)
|
2006-04-19 |
2009-01-07 |
Genentech, Inc. |
Neuartige genunterbrechungen, dazugehörige zusammensetzungen und verfahren
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US8304451B2
(en)
|
2006-05-03 |
2012-11-06 |
President And Fellows Of Harvard College |
Histone deacetylase and tubulin deacetylase inhibitors
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
EP2016101A2
(de)
*
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Bindung von polypeptiden mit optimierten gerüsten
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
KR101454508B1
(ko)
|
2006-05-30 |
2014-11-04 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
KR20090027227A
(ko)
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-dll4 항체 및 이의 사용 방법
|
ES2718952T3
(es)
|
2006-06-07 |
2019-07-05 |
Bioalliance Cv |
Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD-43 y CEA expresados en células cancerosas y métodos que los usan
|
CA2655080A1
(en)
|
2006-06-14 |
2007-12-21 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
DE102006030028A1
(de)
*
|
2006-06-29 |
2008-02-14 |
Forschungszentrum Jülich GmbH |
Verfahren zum Auffinden von spezifisch an einen Köder bindende Moleküle, sowie spezifisch an einen Köder bindende Moleküle und deren Verwendung
|
CA2651992A1
(en)
|
2006-06-30 |
2008-01-10 |
Abbott Biotechnology Ltd. |
Automatic injection device
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
KR20170014023A
(ko)
|
2006-07-05 |
2017-02-07 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
EP2044122B1
(de)
*
|
2006-07-18 |
2018-03-28 |
Sanofi |
Antagonisten-antikörper gegen epha-2 zur krebsbehandlung
|
PT2511301T
(pt)
|
2006-08-04 |
2018-03-08 |
Medimmune Ltd |
Anticorpos humanos para erbb2
|
US8586006B2
(en)
|
2006-08-09 |
2013-11-19 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
DK2484696T3
(en)
|
2006-08-28 |
2017-10-02 |
Kyowa Hakko Kirin Co Ltd |
Antagonistic hLIGHT-specific human monoclonal antibodies
|
WO2008030122A1
(en)
|
2006-09-07 |
2008-03-13 |
University Of Otago |
Biomarkers
|
WO2008127271A2
(en)
|
2006-09-08 |
2008-10-23 |
Abbott Laboratories |
Interleukin -13 binding proteins
|
CA2662755C
(en)
*
|
2006-09-08 |
2017-04-04 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
PT2061878E
(pt)
*
|
2006-09-08 |
2014-04-22 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
CN106008699A
(zh)
*
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
JP2010503407A
(ja)
|
2006-09-12 |
2010-02-04 |
ジェネンテック・インコーポレーテッド |
癌の診断及び治療のための方法及び組成物
|
WO2008034161A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Phylogica Limited |
Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
|
EP3569245A1
(de)
|
2006-09-26 |
2019-11-20 |
Genmab A/S |
Kombinationsbehandlung von cd38-exprimierenden tumoren
|
BRPI0717431A2
(pt)
*
|
2006-09-29 |
2013-11-12 |
Oncomed Pharm Inc |
Composições e métodos de diagnóstico e tratamento do câncer
|
CA2665644A1
(en)
*
|
2006-10-12 |
2008-05-29 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
AU2007308145A1
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
EP2407548A1
(de)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(de)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
US20080096193A1
(en)
*
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
WO2008052187A2
(en)
|
2006-10-27 |
2008-05-02 |
Genentech. Inc. |
Antibodies and immunoconjugates and uses therefor
|
JP5680302B2
(ja)
|
2006-10-30 |
2015-03-04 |
プロメガ コーポレイションPromega Corporation |
キネティクス及び機能発現が高められた突然変異形ヒドロラーゼ・タンパク質
|
ES2541546T3
(es)
|
2006-11-03 |
2015-07-21 |
Wyeth Llc |
Sustancias que inhiben la glucólisis en cultivo celular
|
JP2010510235A
(ja)
|
2006-11-15 |
2010-04-02 |
ファンクショナル・ジェネティクス・インコーポレーテッド |
抗tsg101抗体およびウイルス感染の処置のためのその使用
|
US7488807B2
(en)
|
2006-11-22 |
2009-02-10 |
3M Innovative Properties Company |
Antibody with protein A selectivity
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8067179B2
(en)
*
|
2006-11-30 |
2011-11-29 |
Research Development Foundation |
Immunoglobulin libraries
|
CA2699837C
(en)
|
2006-12-01 |
2017-06-13 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
EP2121979B1
(de)
|
2006-12-05 |
2017-07-12 |
Decode Genetics EHF |
Genetische marker für das risikomanagement bei herzrhythmusstörungen
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
AU2007333735A1
(en)
|
2006-12-19 |
2008-06-26 |
Genentech, Inc. |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
RU2554747C9
(ru)
|
2006-12-20 |
2015-10-20 |
Ксома (Сша) Ллс |
Способы лечения il-1бета-зависимых заболеваний
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
EP2913341A1
(de)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
EP2114443A4
(de)
|
2006-12-29 |
2011-08-10 |
Abbott Lab |
Doppelt spezifische il-1a/il-1b-antikörper
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
GEP20125693B
(en)
|
2007-01-09 |
2012-11-26 |
Biogen Idec Inc |
Sp35 antibodies and usage thereof
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
WO2008092002A2
(en)
|
2007-01-24 |
2008-07-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
US8664364B2
(en)
|
2007-01-24 |
2014-03-04 |
Carnegie Mellon University |
Optical biosensors
|
AU2008212117B2
(en)
|
2007-02-07 |
2014-09-11 |
Decode Genetics Ehf. |
Genetic variants contributing to risk of prostate cancer
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
WO2008101184A2
(en)
*
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
WO2008102380A1
(en)
|
2007-02-21 |
2008-08-28 |
Decode Genetics Ehf |
Genetic susceptibility variants associated with cardiovascular disease
|
CN101663407B
(zh)
|
2007-02-22 |
2017-08-08 |
健泰科生物技术公司 |
用于检测炎性肠病的方法
|
US7771947B2
(en)
*
|
2007-02-23 |
2010-08-10 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
EP3118221B1
(de)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteine
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2121919B1
(de)
|
2007-03-22 |
2012-02-08 |
Heptares Therapeutics Limited |
Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür
|
CN101679521B
(zh)
|
2007-03-22 |
2014-03-12 |
拜奥根Idec马萨诸塞公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008121301A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human il-12 antibodies
|
EP2703007A1
(de)
|
2007-03-30 |
2014-03-05 |
MedImmune, LLC |
Antikörper mit verminderten Deamidierungsprofilen
|
ES2385114T3
(es)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Polipéptidos de FGF-21 modificados y sus usos
|
CN101808661A
(zh)
|
2007-04-02 |
2010-08-18 |
安进弗里蒙特公司 |
抗IgE抗体
|
ATE501280T1
(de)
*
|
2007-04-04 |
2011-03-15 |
Chimera Biotec Gmbh |
Verfahren zum nachweis eines analyten in einer biologischen matrix
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
KR20150067772A
(ko)
|
2007-04-13 |
2015-06-18 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
변형 제vii 인자 폴리펩타이드 및 이의 용도
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
EP2164868B1
(de)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
|
EP2737907A3
(de)
|
2007-05-07 |
2014-11-05 |
MedImmune, LLC |
Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
|
WO2008143666A2
(en)
*
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
HUE036885T2
(hu)
|
2007-05-14 |
2018-08-28 |
Astrazeneca Ab |
Eljárás a bazofil-szint csökkentésére
|
CN101772578A
(zh)
|
2007-05-25 |
2010-07-07 |
解码遗传学私营有限责任公司 |
作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体
|
US7906149B2
(en)
*
|
2007-05-25 |
2011-03-15 |
Boval Company, L.P. |
Method for treating allergic dermatitis
|
US20090175847A1
(en)
*
|
2007-05-30 |
2009-07-09 |
Abbott Laboratories |
Humanized antibodies to ab (20-42) globulomer and uses thereof
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
US8138313B2
(en)
|
2007-06-15 |
2012-03-20 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Treatment of tumors using specific anti-L1 antibody
|
WO2008154700A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Phylogica Limited |
Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
|
JP5718637B2
(ja)
|
2007-06-21 |
2015-05-13 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
JP5602625B2
(ja)
|
2007-06-26 |
2014-10-08 |
エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング |
結合物質のディスプレイ
|
EP3424529A1
(de)
|
2007-07-02 |
2019-01-09 |
Oncomed Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
WO2009015063A2
(en)
|
2007-07-23 |
2009-01-29 |
Centocor |
Methods and compositions for treating fibrosis related disorders using il-17 antagonists
|
US8986684B2
(en)
*
|
2007-07-25 |
2015-03-24 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating autoimmune disease
|
WO2009020477A1
(en)
*
|
2007-08-06 |
2009-02-12 |
Yale University |
Modified miniature proteins
|
CA2694364C
(en)
|
2007-08-21 |
2016-11-22 |
Morphosys Ag |
Improved methods for the formation of disulphide bonds
|
EP2193142B1
(de)
*
|
2007-08-30 |
2015-01-07 |
CureDM Group Holdings, LLC |
Zusammensetzungen und verfahren zur anwendung von proinselzellpeptiden und analoga davon
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
MX2010002661A
(es)
|
2007-09-14 |
2010-05-20 |
Adimab Inc |
Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
CN104004088B
(zh)
|
2007-09-26 |
2017-11-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
NZ584330A
(en)
*
|
2007-10-04 |
2013-01-25 |
Bionomics Ltd |
Markers of endothelial cells and uses thereof
|
EP2219452B1
(de)
|
2007-11-05 |
2015-10-14 |
MedImmune, LLC |
Verfahren zur behandlung von skleroderm
|
EP3360567A1
(de)
|
2007-11-07 |
2018-08-15 |
Genentech, Inc. |
Amp zur verwendung in der behandlung von mikrobiellen erkrankungen
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
JP5547083B2
(ja)
*
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
US8697360B2
(en)
|
2007-11-30 |
2014-04-15 |
Decode Genetics Ehf. |
Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
|
TWI580694B
(zh)
*
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US8426153B2
(en)
|
2007-12-03 |
2013-04-23 |
Carnegie Mellon University |
Linked peptides fluorogenic biosensors
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
EP3587450A1
(de)
|
2007-12-17 |
2020-01-01 |
Pfizer Limited |
Behandlung von interstitieller cystitis mit ngf inhibitoren
|
US7982017B2
(en)
|
2007-12-18 |
2011-07-19 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
WO2009086003A1
(en)
|
2007-12-20 |
2009-07-09 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
US8637026B2
(en)
|
2007-12-26 |
2014-01-28 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
SG186689A1
(en)
|
2007-12-28 |
2013-01-30 |
Univ Tennessee Res Foundation |
Treatment and prophylaxis of amyloidosis
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
CA2711771C
(en)
|
2008-01-11 |
2017-01-24 |
Gene Techno Science Co., Ltd. |
Humanized anti-.alpha.9 integrin antibodies and the uses thereof
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
AU2009210636B2
(en)
|
2008-01-31 |
2014-08-28 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
EP2247743B1
(de)
|
2008-02-08 |
2016-04-06 |
Ambrx, Inc. |
Modifizierte leptin-polypeptide und deren verwendungen
|
MX2010008578A
(es)
|
2008-02-08 |
2010-11-10 |
Medimmune Llc |
Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
EP2247755B1
(de)
|
2008-02-14 |
2015-01-28 |
Decode Genetics EHF |
Suszeptibilitätsvarianten für lungenkrebs
|
AU2009219358A1
(en)
|
2008-02-28 |
2009-09-03 |
3M Innovative Properties Company |
Antibodies to Clostridium difficile spores and uses thereof
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009109572A2
(en)
*
|
2008-03-03 |
2009-09-11 |
Ablynx Nv |
Monovalent phage display of single variable domains
|
US8293239B2
(en)
|
2008-03-04 |
2012-10-23 |
Pfizer Limited |
Methods of treating chronic pain
|
BRPI0908276B8
(pt)
|
2008-03-04 |
2021-05-25 |
Labrys Biologics Inc |
uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
JP2011516038A
(ja)
|
2008-03-12 |
2011-05-26 |
オタゴ イノベーション リミテッド |
バイオマーカー
|
JP5818440B2
(ja)
|
2008-03-12 |
2015-11-18 |
オタゴ イノベーション リミテッド |
バイオマーカー
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
TWI461210B
(zh)
|
2008-03-18 |
2014-11-21 |
Abbvie Inc |
治療牛皮癬的方法
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
WO2009124090A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing asthma
|
EP2274450A2
(de)
|
2008-04-01 |
2011-01-19 |
Decode Genetics EHF |
Suszeptibilitätsvarianten bei peripherer arterienkrankheit und bauchschlagader-aneurysma
|
MX2010010737A
(es)
|
2008-04-02 |
2010-12-20 |
Macrogenics Inc |
Anticuerpos especificos para her2/neu y metodos para utilizar los mismos.
|
CN102046655B
(zh)
|
2008-04-02 |
2016-09-14 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
CN102056626B
(zh)
|
2008-04-11 |
2016-07-06 |
西雅图遗传学公司 |
胰腺癌、卵巢癌和其它癌症的检测和治疗
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
WO2009132287A2
(en)
|
2008-04-24 |
2009-10-29 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
KR101746861B1
(ko)
|
2008-04-24 |
2017-06-14 |
가부시키가이샤 진 테크노 사이언스 |
세포 외 기질 단백질의 아미노산 서열 rgd에 특이적인 인간화된 항체 및 그의 용도
|
MX2010011679A
(es)
|
2008-04-25 |
2011-05-23 |
Dyax Corp |
Anticuerpos contra el receptor fc neonatal y uso de los mismos.
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
MX2010011955A
(es)
|
2008-04-29 |
2011-01-21 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
JP5624535B2
(ja)
|
2008-05-02 |
2014-11-12 |
シアトル ジェネティクス,インコーポレーテッド |
低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
DK2280996T3
(en)
|
2008-05-06 |
2016-12-19 |
Genentech Inc |
Affinity matured CRIg VARIANTS
|
CN104558178A
(zh)
|
2008-05-09 |
2015-04-29 |
Abbvie公司 |
针对渐进性糖化终极产物受体(rage)的抗体及其用途
|
PL2279004T3
(pl)
*
|
2008-05-16 |
2015-06-30 |
Hoffmann La Roche |
Zastosowanie biomarkerów do oceny leczenia zaburzeń zapalnych przewodu pokarmowego antagonistami integryny beta7
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2599793A1
(de)
|
2008-05-29 |
2013-06-05 |
Nuclea Biotechnologies, Inc. |
Anti-Phosphor-AKT-Antikörper
|
US9035027B2
(en)
|
2008-06-03 |
2015-05-19 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
NZ589436A
(en)
|
2008-06-03 |
2012-12-21 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
CA2726845C
(en)
|
2008-06-04 |
2017-09-26 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2010004591A2
(en)
|
2008-07-07 |
2010-01-14 |
Decode Genetics Ehf |
Genetic variants for breast cancer risk assessment
|
ME02069B
(me)
|
2008-07-08 |
2015-05-20 |
Oncomed Pharm Inc |
Vezujuci agensi notch1 receptora i postupci njihove primene
|
EP2310049A4
(de)
|
2008-07-08 |
2013-06-26 |
Abbvie Inc |
Prostaglandin-e2 bindende proteine und ihre verwendung
|
NZ590074A
(en)
|
2008-07-08 |
2012-12-21 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
JP2011527572A
(ja)
|
2008-07-09 |
2011-11-04 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Lingo抗体または断片を含む組成物
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
KR101708946B1
(ko)
|
2008-07-23 |
2017-02-21 |
다나-파버 캔서 인스티튜트 인크. |
탈아세틸화제 억제제 및 그것의 용도
|
MX2011000859A
(es)
*
|
2008-07-23 |
2011-02-24 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados y sus usos.
|
US9182406B2
(en)
*
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
MX2011000847A
(es)
|
2008-08-06 |
2011-02-25 |
Novo Nordisk Healthcare Ag |
Proteinas conjugadas con eficacia prolongada in vivo.
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
US9023594B2
(en)
|
2008-09-05 |
2015-05-05 |
President And Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
US20100093563A1
(en)
*
|
2008-09-22 |
2010-04-15 |
Robert Anthony Williamson |
Methods and vectors for display of molecules and displayed molecules and collections
|
WO2010033237A2
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
EP2344180A2
(de)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Verfahren zur vorhersage der produktion von aktivierenden signalen durch vernetzende bindungsproteine
|
CA2738019A1
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
MX2011003183A
(es)
|
2008-09-26 |
2011-04-21 |
Oncomed Pharm Inc |
Agentes que se unen a receptor encrespado y usos de los mismos.
|
CA2737026C
(en)
|
2008-09-26 |
2019-12-24 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
PL2337846T3
(pl)
|
2008-09-26 |
2018-06-29 |
Ambrx, Inc. |
Mikroorganizmy i szczepionki z replikacją zależną od nie-naturalnych aminokwasów
|
CA2736904A1
(en)
|
2008-09-26 |
2010-04-01 |
Wyeth Llc |
Compatible display vector systems
|
SI2342226T1
(sl)
|
2008-09-26 |
2016-11-30 |
Dana-Farber Cancer Institute Inc. |
Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
|
PT3335728T
(pt)
|
2008-10-10 |
2020-02-19 |
Childrens Medical Center |
Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada
|
EP2349329A4
(de)
|
2008-10-14 |
2012-10-31 |
Dyax Corp |
Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
|
WO2010141039A1
(en)
|
2008-10-20 |
2010-12-09 |
Abbott Laboratories |
Isolation and purification of antibodies using protein a affinity chromatography
|
CA2741040C
(en)
|
2008-10-20 |
2015-09-22 |
Gwangju Institute Of Science And Technology |
Bipodal-peptide binder
|
WO2010048615A2
(en)
|
2008-10-24 |
2010-04-29 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention |
Human ebola virus species and compositions and methods thereof
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
ES2732504T3
(es)
|
2008-10-29 |
2019-11-22 |
Circular Commitment Company |
Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
LT2356269T
(lt)
|
2008-10-31 |
2016-09-12 |
Janssen Biotech, Inc. |
Karkaso kompozicijos iii tipo fibronektino domeno pagrindu, būdai ir panaudojimas
|
CA2742968C
(en)
|
2008-11-07 |
2020-06-09 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
CA3035432A1
(en)
|
2008-11-10 |
2010-05-14 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
PT2356462T
(pt)
|
2008-11-11 |
2017-04-07 |
Univ Michigan Regents |
Composições e métodos anti-cxcr1
|
WO2010056804A1
(en)
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
DK2189539T4
(en)
*
|
2008-11-21 |
2018-09-17 |
Chimera Biotec Gmbh |
Conjugate complexes for analyte detection
|
CA2744158A1
(en)
|
2008-11-22 |
2010-05-27 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of breast cancer
|
RU2011121042A
(ru)
|
2008-11-26 |
2013-01-10 |
Файв Прайм Терапеутикс, Инк. |
Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
|
JP5520961B2
(ja)
|
2008-11-28 |
2014-06-11 |
エモリー ユニバーシティ |
感染症および腫瘍を処置するための方法
|
CA2745271A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
LT4209510T
(lt)
|
2008-12-09 |
2024-03-12 |
F. Hoffmann-La Roche Ag |
Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui
|
PL2786762T3
(pl)
|
2008-12-19 |
2019-09-30 |
Macrogenics, Inc. |
Kowalencyjne diabody i ich zastosowania
|
KR20140020368A
(ko)
|
2008-12-23 |
2014-02-18 |
제넨테크, 인크. |
암 환자에서의 진단 목적용 방법 및 조성물
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010085510A1
(en)
|
2009-01-20 |
2010-07-29 |
Zadeh Homayoun H |
Antibody mediated osseous regeneration
|
JP2012515544A
(ja)
|
2009-01-21 |
2012-07-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Pta089タンパク質
|
TWI504405B
(zh)
|
2009-01-22 |
2015-10-21 |
Novo Nordisk Healthcare Ag |
穩定的生長激素化合物
|
EP2391748A4
(de)
*
|
2009-01-28 |
2012-08-01 |
Antigen Express Inc |
Li-key-hybridpeptide zur modulation der immunreaktion auf influenza
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
AU2010208637A1
(en)
|
2009-01-29 |
2011-08-04 |
Abbvie Inc. |
IL-1 binding proteins
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(de)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
|
EP2396011B1
(de)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
|
AU2010216152B2
(en)
*
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
WO2010096388A2
(en)
|
2009-02-18 |
2010-08-26 |
Carnegie Mellon University |
Quenched dendrimeric dyes for bright detection
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
WO2010102167A1
(en)
|
2009-03-05 |
2010-09-10 |
Becton, Dickinson And Company |
Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
SG173705A1
(en)
|
2009-03-05 |
2011-09-29 |
Abbott Lab |
Il-17 binding proteins
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
JP2012524521A
(ja)
|
2009-03-06 |
2012-10-18 |
トライパス イメージング インコーポレイテッド |
グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
|
AU2010221993C1
(en)
|
2009-03-10 |
2015-07-09 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized K33N monoclonal antibody
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
CN103755808B
(zh)
|
2009-03-25 |
2016-02-10 |
霍夫曼-拉罗奇有限公司 |
抗-α5β1抗体及其应用
|
BRPI1006448B1
(pt)
|
2009-03-25 |
2021-08-17 |
Genentech, Inc |
Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
CN102449165B
(zh)
|
2009-04-03 |
2014-07-09 |
解码遗传学私营有限责任公司 |
用于心房颤动和中风的风险管理的遗传标志
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
AP2011005984A0
(en)
|
2009-04-20 |
2011-12-31 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17.
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
US8765916B2
(en)
|
2009-04-29 |
2014-07-01 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
ERG monoclonal antibodies
|
CA2760237C
(en)
|
2009-04-29 |
2017-11-14 |
Abbott Biotechnology Ltd. |
Automatic injection device and plunger for same
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
AU2010249470B2
(en)
*
|
2009-05-20 |
2015-06-25 |
Novimmune S.A. |
Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
|
US8680055B2
(en)
|
2009-06-03 |
2014-03-25 |
University Of Southern California |
Methods for decreasing steroidogenesis in prostate cancer cells
|
CN106390107B
(zh)
|
2009-06-10 |
2019-12-31 |
纽约大学 |
病理tau蛋白的免疫靶向
|
EP2261242A1
(de)
|
2009-06-10 |
2010-12-15 |
Universite Catholique De Louvain |
Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
CN102481380A
(zh)
|
2009-07-09 |
2012-05-30 |
霍夫曼-拉罗奇有限公司 |
体内肿瘤血管系统成像
|
US8796182B2
(en)
|
2009-07-10 |
2014-08-05 |
Decode Genetics Ehf. |
Genetic markers associated with risk of diabetes mellitus
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
BR112012002083A2
(pt)
|
2009-07-31 |
2016-11-08 |
Genentech Inc |
inibição de metaste tumoral
|
CN102596220A
(zh)
|
2009-07-31 |
2012-07-18 |
韦恩州立大学 |
单磷酸化的脂质a衍生物
|
US9259476B2
(en)
|
2009-07-31 |
2016-02-16 |
Wayne State University |
Monophosphorylated lipid A derivatives
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
WO2011019393A2
(en)
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
ES2793348T3
(es)
|
2009-08-11 |
2020-11-13 |
Hoffmann La Roche |
Producción de proteínas en medios de cultivo celular libres de glutamina
|
JP5762408B2
(ja)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法
|
SG178419A1
(en)
|
2009-08-15 |
2012-04-27 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
RU2535074C2
(ru)
|
2009-08-28 |
2014-12-10 |
Лэйбрис Байолоджикс, Инк. |
Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
|
CA2771575A1
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
CA2772628A1
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
EP2477654A4
(de)
|
2009-09-14 |
2013-01-23 |
Abbott Lab |
Verfahren zur behandlung von schuppenflechte
|
JP2013504602A
(ja)
*
|
2009-09-14 |
2013-02-07 |
ダイアックス コーポレーション |
新しく設計したhccdr3を含む遺伝子パッケージライブラリー
|
AU2010297344A1
(en)
|
2009-09-17 |
2012-02-23 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
AU2010298025B2
(en)
|
2009-09-25 |
2016-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 and their use
|
WO2011036555A1
(en)
|
2009-09-25 |
2011-03-31 |
University Of Oslo |
Multivalent phage display systems and methods
|
CA2772945A1
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
CA2774999A1
(en)
|
2009-09-30 |
2011-04-07 |
President And Fellows Of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
EP2470569A1
(de)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antikörper gegen epha10
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
AR078651A1
(es)
|
2009-10-15 |
2011-11-23 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2488204B1
(de)
|
2009-10-16 |
2016-04-06 |
Oncomed Pharmaceuticals, Inc. |
Therapeutische kombination und verwendungg mit dll4-antagonistische antikörper und mittel gegen bluthochdruck
|
RS60577B1
(sr)
|
2009-10-20 |
2020-08-31 |
Abbvie Inc |
Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
MX2012004647A
(es)
|
2009-10-22 |
2012-06-19 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso.
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
EP2496605A1
(de)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 als therapeutisches und diagnostisches ziel
|
WO2011056073A2
(en)
|
2009-11-04 |
2011-05-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
BR112012010153B1
(pt)
|
2009-11-05 |
2022-05-03 |
Genentech, Inc |
Método de produção de um anticorpo
|
WO2011058087A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
CA3061784C
(en)
|
2009-11-13 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
CA2781887C
(en)
|
2009-11-30 |
2018-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
PT2510011E
(pt)
|
2009-12-09 |
2014-12-12 |
Inst Nat Santé Et De La Rech Médicale |
Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
ES2594893T3
(es)
*
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
PE20121799A1
(es)
|
2009-12-21 |
2013-01-02 |
Ambrx Inc |
Polipeptidos de somatotropina porcina modificados y sus usos
|
PL2515941T3
(pl)
|
2009-12-21 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Preparat farmaceutyczny zawierający bewacyzumab
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
AU2010336485B2
(en)
|
2009-12-23 |
2015-03-26 |
Genentech, Inc. |
Anti-Bv8 antibodies and uses thereof
|
WO2011079283A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Bioalliance C.V. |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
EP2521568B1
(de)
|
2010-01-06 |
2018-07-25 |
Dyax Corp. |
Plasmakallikreinbindende proteine
|
SG182408A1
(en)
|
2010-01-11 |
2012-08-30 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
WO2011091134A2
(en)
|
2010-01-22 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
EP2525833A2
(de)
|
2010-01-22 |
2012-11-28 |
Novo Nordisk Health Care AG |
Stabile wachstumshormonverbindungen
|
WO2011089255A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
MX2012008985A
(es)
|
2010-02-02 |
2012-09-07 |
Abbott Biotech Ltd |
Metodos y composiciones para predecir la capacidad de respuesta al tratamiento con el inhibidor de tnf-alfa.
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 항체 및 이의 용도
|
US10393754B2
(en)
|
2010-02-17 |
2019-08-27 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating heart failure
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
ES2519348T3
(es)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
|
KR20180028561A
(ko)
|
2010-02-23 |
2018-03-16 |
제넨테크, 인크. |
난소암의 치료를 위한 항혈관신생 요법
|
EP2538981B1
(de)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und methoden zur diagnose und behandlung von tumoren
|
SG10201501342UA
(en)
|
2010-02-24 |
2015-04-29 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
PE20130580A1
(es)
|
2010-03-02 |
2013-06-02 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
EP2542578A1
(de)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c und hirnkrebs
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
HUE046360T2
(hu)
|
2010-03-12 |
2020-03-30 |
Debiopharm Int Sa |
CD37-kötõ molekulák és azok immunkonjugátumai
|
DK2547359T3
(en)
|
2010-03-15 |
2016-06-06 |
The Board Of Trustees Of The Univ Of Illionis |
Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
|
WO2011116276A2
(en)
*
|
2010-03-18 |
2011-09-22 |
Matthew Delisa |
Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
|
WO2013040142A2
(en)
|
2011-09-16 |
2013-03-21 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
EP2550529B1
(de)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
BR112012022044A2
(pt)
|
2010-03-24 |
2020-08-25 |
Genentech Inc |
''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
ES2717883T3
(es)
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
NZ602700A
(en)
|
2010-04-01 |
2014-10-31 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
JP6038777B2
(ja)
|
2010-05-03 |
2016-12-07 |
ユニバーシティー オブ ロチェスター |
黄色ブドウ球菌(Staphylococcusaureus)感染のための抗グルコサミニダーゼ受動免疫化
|
EP2569335B1
(de)
|
2010-05-14 |
2018-08-22 |
Orega Biotech |
Verfahren zur behandlung und/oder prävention von zellproliferationsstörungen mit il-17-antagonisten
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
EP2577309B1
(de)
|
2010-05-25 |
2016-11-23 |
Carnegie Mellon University |
Gezielte sonden für zellphysiologie
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
ES2685607T3
(es)
|
2010-06-03 |
2018-10-10 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
|
WO2012047324A2
(en)
|
2010-06-10 |
2012-04-12 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
RU2013101779A
(ru)
|
2010-06-16 |
2014-07-27 |
Эббви Инк. |
Сравнение образцов белков
|
CN103080136B
(zh)
|
2010-06-18 |
2015-08-12 |
霍夫曼-拉罗奇有限公司 |
抗Axl抗体及使用方法
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
BR112013000340A2
(pt)
|
2010-07-09 |
2016-05-31 |
Genentech Inc |
anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CA3086837C
(en)
|
2010-07-16 |
2023-03-07 |
Adimab, Llc |
Libraries comprising segmental pools, and methods for their preparation and use
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
EP3246335A3
(de)
|
2010-07-19 |
2017-12-27 |
Otago Innovation Limited |
Signalbiomarker
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
EP2595661A1
(de)
|
2010-07-22 |
2013-05-29 |
Novo Nordisk Health Care AG |
Wachstumshormonkonjugate
|
CN103261225A
(zh)
|
2010-07-23 |
2013-08-21 |
波士顿大学董事会 |
作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
EP2601609B1
(de)
|
2010-08-02 |
2017-05-17 |
Population Bio, Inc. |
Zusammensetzungen und verfahren zur erkennung der verursachenden mutationen in genetischen erkrankungen
|
MX339622B
(es)
|
2010-08-02 |
2016-06-02 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2600895A1
(de)
|
2010-08-03 |
2013-06-12 |
Hoffmann-La Roche AG |
Biomarker für chronische lymphatische leukämie (cll)
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
RU2013106217A
(ru)
|
2010-08-05 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Гибридный белок из антитела против мнс и противовирусного цитокина
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
EA037977B1
(ru)
|
2010-08-13 |
2021-06-18 |
Роше Гликарт Аг |
Антитела к fap, способы их получения и применения
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
AU2011291943B2
(en)
|
2010-08-17 |
2015-01-22 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
WO2012022774A1
(en)
|
2010-08-19 |
2012-02-23 |
Roche Diagnostics Gmbh |
An assay for measurement of antibodies binding to a therapeutic monoclonal antibody
|
HUE058226T2
(hu)
|
2010-08-19 |
2022-07-28 |
Zoetis Belgium S A |
NGF elleni antitestek és alkalmazásuk
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
CA2809369A1
(en)
|
2010-08-27 |
2012-03-01 |
Stem Centrx, Inc. |
Notum protein modulators and methods of use
|
RU2013114360A
(ru)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
Биомаркеры и способы лечения
|
NZ608814A
(en)
|
2010-09-03 |
2015-06-26 |
Stem Centrx Inc |
Novel modulators and methods of use
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
US20120122076A1
(en)
|
2010-09-20 |
2012-05-17 |
Abbott Laboratories |
Purification of antibodies using simulated moving bed chromatography
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
EP2446898A1
(de)
|
2010-09-30 |
2012-05-02 |
Laboratorios Del. Dr. Esteve, S.A. |
Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
|
US9005907B2
(en)
|
2010-10-01 |
2015-04-14 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
US9238690B2
(en)
|
2010-10-29 |
2016-01-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
TW201300417A
(zh)
|
2010-11-10 |
2013-01-01 |
Genentech Inc |
用於神經疾病免疫療法之方法及組合物
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
EP2640425A2
(de)
|
2010-11-18 |
2013-09-25 |
Beth Israel Deaconess Medical Center, Inc. |
Verfahren zur behandlung von adipositas durch hemmung von nicotinamid-n-methyl-transferase (nnmt)
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
US9783602B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
SG191081A1
(en)
|
2010-12-08 |
2013-07-31 |
Stem Centrx Inc |
Novel modulators and methods of use
|
BR122020012255B1
(pt)
|
2010-12-16 |
2022-08-09 |
Genentech, Inc |
Uso de um anticorpo anti-il-13, usos de um inibidor da via de th2 e anticorpos anti-periostina
|
AU2011349443B2
(en)
|
2010-12-20 |
2015-12-24 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
US9029502B2
(en)
|
2010-12-20 |
2015-05-12 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
RU2627171C2
(ru)
|
2010-12-21 |
2017-08-03 |
Эббви Инк. |
Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
KR20130118925A
(ko)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
항-pcsk9 항체 및 사용 방법
|
WO2012088381A2
(en)
|
2010-12-22 |
2012-06-28 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
US20140038842A1
(en)
|
2010-12-28 |
2014-02-06 |
Xoma Technology |
Cell surface display using pdz domains
|
US9598499B2
(en)
|
2010-12-30 |
2017-03-21 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CA2822481A1
(en)
|
2011-01-03 |
2012-07-12 |
F. Hoffmann-La Roche Ag |
A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
PT2663577T
(pt)
|
2011-01-14 |
2017-07-19 |
Ucb Biopharma Sprl |
Anticorpo de ligação a il-17a e il-17f
|
EP2749305B1
(de)
|
2011-01-24 |
2017-11-01 |
AbbVie Biotechnology Ltd |
Automatische Injektionsvorrichtungen mit umspritzten Greifflächen
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
AR085141A1
(es)
|
2011-02-03 |
2013-09-11 |
Alexion Pharma Inc |
Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
BR112013022208A2
(pt)
|
2011-03-02 |
2022-03-08 |
Berg Llc |
Ensaios baseados em investigação celular e usos destes
|
WO2012122219A2
(en)
|
2011-03-07 |
2012-09-13 |
University Of Louisville Research Foundation |
Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
GB2503604B
(en)
|
2011-03-21 |
2020-04-22 |
Biodesy Llc |
Classification of kinase inhibitors using second harmonic optical techniques
|
WO2012128810A1
(en)
|
2011-03-23 |
2012-09-27 |
Abbott Laboratories |
Methods and systems for the analysis of protein samples
|
MY163539A
(en)
|
2011-03-29 |
2017-09-15 |
Roche Glycart Ag |
Antibody fc variants
|
WO2012131053A1
(en)
|
2011-03-30 |
2012-10-04 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
US9777332B2
(en)
|
2011-03-31 |
2017-10-03 |
St. Jude Children's Research Hospital |
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
NZ616308A
(en)
|
2011-04-08 |
2016-03-31 |
Biogen Ma Inc |
Biomarkers predictive of therapeutic responsiveness to ifnβ and uses thereof
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
US10352936B2
(en)
|
2011-04-14 |
2019-07-16 |
Apoplogic Pharmaceuticals, Inc. |
Use of tumor Fas expression to determine response to anti-cancer therapy
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン,エルエルシー |
B7−h1およびpd−1に結合する抗体およびその他の分子
|
AU2012245073B2
(en)
|
2011-04-21 |
2016-02-11 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
US20140141458A1
(en)
|
2011-05-12 |
2014-05-22 |
The Johns Hopkins University |
Assay reagents for a neurogranin diagnostic kit
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
SG194917A1
(en)
|
2011-05-16 |
2013-12-30 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
EP2714738B1
(de)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalente und monovalente multispezifische komplexe und ihre verwendungen
|
MX343659B
(es)
|
2011-06-02 |
2016-11-16 |
Dyax Corp |
Proteínas de unión receptoras fc.
|
HRP20211582T1
(hr)
|
2011-06-03 |
2022-01-07 |
Xoma Technology Ltd. |
Protutijela specifična za tgf-beta
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
CA2832109C
(en)
|
2011-06-10 |
2021-07-06 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
HUE038509T2
(hu)
|
2011-06-10 |
2018-10-29 |
Medimmune Ltd |
Pseudomonas PSL elleni kötõmolekula és alkalmazása
|
US8623666B2
(en)
|
2011-06-15 |
2014-01-07 |
Hoffmann-La Roche Inc. |
Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
|
EA031181B1
(ru)
|
2011-06-28 |
2018-11-30 |
Оксфорд Байотерепьютикс Лтд. |
Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
|
LT2726094T
(lt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Gydymo ir diagnozavimo objektas
|
BR112013030472A2
(pt)
|
2011-06-30 |
2019-09-24 |
Genentech Inc |
formulação farmacêutica, artigo de fabricação e método
|
WO2013009521A2
(en)
|
2011-07-13 |
2013-01-17 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
US20140161821A1
(en)
|
2011-07-14 |
2014-06-12 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
WO2013012747A1
(en)
|
2011-07-15 |
2013-01-24 |
Oncomed Pharmaceuticals, Inc. |
Rspo binding agents and uses thereof
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
TR201820873T4
(tr)
|
2011-08-01 |
2019-01-21 |
Hoffmann La Roche |
Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
US20130058936A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
WO2013028817A1
(en)
|
2011-08-23 |
2013-02-28 |
Foundation Medicine , Inc. |
Novel kif5b-ret fusion molecules and uses thereof
|
JP6060162B2
(ja)
|
2011-08-23 |
2017-01-11 |
ロシュ グリクアート アーゲー |
2つのFabフラグメントを含むFc不含抗体および使用方法
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2753697A1
(de)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
|
JP6216317B2
(ja)
|
2011-09-09 |
2017-10-18 |
メディミューン リミテッド |
抗Siglec−15抗体およびその使用
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
WO2013039996A1
(en)
|
2011-09-13 |
2013-03-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using fndc5
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
AU2012312515A1
(en)
|
2011-09-19 |
2014-03-13 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and B-raf antagonists
|
HUE061002T2
(hu)
|
2011-09-23 |
2023-04-28 |
Mereo Biopharma 5 Inc |
VEGF/DLL4-kötõ ágensek és alkalmazásaik
|
US20130089562A1
(en)
|
2011-10-05 |
2013-04-11 |
Genenthech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
AU2012318306A1
(en)
|
2011-10-06 |
2014-04-24 |
The Board Of Trustees Of The University Of Illinois |
Myosin binding protein- C for use in methods relating to diastolic heart failure
|
EP2766483B1
(de)
|
2011-10-10 |
2022-03-23 |
The Hospital For Sick Children |
Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
CA2851371A1
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Zymogen activators
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
WO2013056054A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc |
Peptide inhibitors of bace1
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
US8999331B2
(en)
|
2011-10-24 |
2015-04-07 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
CN104093739A
(zh)
|
2011-10-24 |
2014-10-08 |
艾伯维公司 |
针对tnf的免疫结合剂
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
CA2853943C
(en)
|
2011-11-02 |
2015-12-08 |
University Of Rochester |
Anti-glucosaminidase passive immunization for staphylococcus aureus infections
|
ES2847867T3
(es)
|
2011-11-03 |
2021-08-04 |
Tripath Imaging Inc |
Métodos y composiciones para preparar muestras para inmunotinción
|
EP2773779B1
(de)
|
2011-11-04 |
2020-10-14 |
Population Bio, Inc. |
Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
|
WO2013070615A1
(en)
|
2011-11-07 |
2013-05-16 |
Medlmmune, Llc. |
Combination therapies using anti- pseudomonas psl and pcrv binding molecules
|
US20140286959A1
(en)
|
2011-11-08 |
2014-09-25 |
Pfizer Inc. |
Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
WO2013068432A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
HUE037142T2
(hu)
|
2011-11-11 |
2018-08-28 |
Ucb Biopharma Sprl |
Albumin-kötõ ellenanyagok és kötõfragmenseik
|
BR112014011331A2
(pt)
|
2011-11-11 |
2017-04-25 |
Rinat Neuroscience Corp |
anticorpos específicos para trop-2 e seus usos
|
CN104066481A
(zh)
|
2011-11-21 |
2014-09-24 |
伊缪诺金公司 |
利用egfr抗体细胞毒性剂缀合物治疗抗egfr疗法的肿瘤的方法
|
WO2013078170A1
(en)
|
2011-11-21 |
2013-05-30 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
CN104302669A
(zh)
|
2011-11-23 |
2015-01-21 |
伊格尼卡生物治疗公司 |
抗cd98抗体及其使用方法
|
KR102080535B1
(ko)
|
2011-11-23 |
2020-02-24 |
메디뮨 엘엘씨 |
Her3에 특이적인 결합 분자 및 이의 용도
|
AU2012346861A1
(en)
|
2011-11-30 |
2014-06-19 |
AbbVie Deutschland GmbH & Co. KG |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
CN104136462B
(zh)
|
2011-12-14 |
2017-06-09 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
CN104144947B
(zh)
|
2011-12-14 |
2017-10-27 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
EP3050900A1
(de)
|
2011-12-19 |
2016-08-03 |
Xoma (Us) Llc |
Verfahren zur behandlung von akne
|
EP2794651B1
(de)
|
2011-12-22 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Expressionsvektorelementkombinationen, neue verfahren zur produktionszellenerzeugung und deren verwendung bei der rekombinanten herstellung von polypeptiden
|
EP2794662A1
(de)
|
2011-12-22 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
System zur anzeige eines antikörpers in voller länge für eukaryotische zellen und seine verwendung
|
RU2628703C2
(ru)
|
2011-12-22 |
2017-08-21 |
Ф. Хоффманн-Ля Рош Аг |
Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
SI2802606T1
(en)
|
2012-01-10 |
2018-08-31 |
Biogen Ma Inc. |
Improves the transfer of healing molecules through the hematoencephalic barrier
|
KR20140119114A
(ko)
|
2012-01-18 |
2014-10-08 |
제넨테크, 인크. |
Fgf19 조절제의 사용 방법
|
SG11201404198TA
(en)
|
2012-01-18 |
2014-08-28 |
Genentech Inc |
Anti-lrp5 antibodies and methods of use
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
SG10202006762PA
(en)
|
2012-01-27 |
2020-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
EP2812452B1
(de)
|
2012-02-09 |
2020-05-27 |
Population Bio, Inc. |
Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
|
US10444241B2
(en)
|
2012-02-10 |
2019-10-15 |
Seattle Genetics, Inc. |
Detection and treatment of CD30+ cancers
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
SI2814844T1
(sl)
|
2012-02-15 |
2017-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo in blokirajo sprožilni receptor, izražen na mieloidnih celicah-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
SI2814842T1
(sl)
|
2012-02-15 |
2018-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
|
BR112014018005B1
(pt)
|
2012-02-15 |
2021-06-29 |
F. Hoffmann-La Roche Ag |
Uso de um complexo não covalente imobilizado
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
LT2825558T
(lt)
|
2012-03-13 |
2019-08-12 |
F. Hoffmann-La Roche Ag |
Derinių terapija, skirta kiaušidžių vėžiui gydyti
|
CN104254541A
(zh)
|
2012-03-16 |
2014-12-31 |
弗·哈夫曼-拉罗切有限公司 |
改造的构象稳定蛋白质
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
MX2014010953A
(es)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Metodos para tratamiento de melanoma con inhibidores pak1.
|
IN2014DN08537A
(de)
|
2012-03-20 |
2015-05-15 |
Otago Innovation Ltd |
|
WO2013139956A1
(en)
|
2012-03-22 |
2013-09-26 |
Thrombogenics Nv |
Antibodies abrogating cell binding to lactadherin
|
US9421250B2
(en)
|
2012-03-23 |
2016-08-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
CN104334583A
(zh)
|
2012-03-28 |
2015-02-04 |
弗·哈夫曼-拉罗切有限公司 |
抗-hcmv特应抗体及其用途
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CN110456035A
(zh)
|
2012-04-02 |
2019-11-15 |
博格有限责任公司 |
基于细胞的探询式分析及其应用
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
EA202090591A3
(ru)
|
2012-04-20 |
2020-12-30 |
Мерюс Н.В. |
СПОСОБЫ И СРЕДСТВА ДЛЯ ПОЛУЧЕНИЯ Ig-ПОДОБНЫХ МОЛЕКУЛ
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
CA2871528A1
(en)
|
2012-04-24 |
2013-10-31 |
Thrombogenics N.V. |
Anti-pdgf-c antibodies
|
JP6302460B2
(ja)
|
2012-04-25 |
2018-03-28 |
バイオデシー, インコーポレイテッド |
タンパク質のアロステリックモジュレーターを検出するための方法
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
JP2015518829A
(ja)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
|
ES2766836T3
(es)
|
2012-05-15 |
2020-06-15 |
Eisai Inc |
Métodos para el tratamiento de cáncer gástrico
|
WO2013177118A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
SG10201603055WA
(en)
|
2012-05-31 |
2016-05-30 |
Genentech Inc |
Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
CN104364264B
(zh)
|
2012-06-06 |
2018-07-24 |
硕腾服务有限责任公司 |
犬源化抗ngf抗体和其方法
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
EP2867674B1
(de)
|
2012-06-28 |
2018-10-10 |
UCB Biopharma SPRL |
Verfahren zur identifikation von verbindungen von therapeutischem interesse
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
CN104428006B
(zh)
|
2012-07-04 |
2017-09-08 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原‑抗体缀合物
|
EP3138578B1
(de)
|
2012-07-04 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Anti-theophyllin-antikörper und verfahren zur verwendung davon
|
RU2630296C2
(ru)
|
2012-07-04 |
2017-09-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к биотину и способы их применения
|
US20150184154A1
(en)
|
2012-07-05 |
2015-07-02 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
New treatment for neurodegenerative diseases
|
CN104428416B
(zh)
|
2012-07-05 |
2019-01-29 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
JP2015527318A
(ja)
|
2012-07-09 |
2015-09-17 |
ジェネンテック, インコーポレイテッド |
抗cd22を含む免疫複合体
|
AU2013288930A1
(en)
|
2012-07-09 |
2014-12-04 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD79b antibodies
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
CA2874554C
(en)
|
2012-07-13 |
2019-12-03 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9297806B2
(en)
|
2012-08-01 |
2016-03-29 |
The Johns Hopkins University |
5-hydroxymethylcytosine in human cancer
|
EP2879710B1
(de)
|
2012-08-03 |
2019-11-13 |
Dana-Farber Cancer Institute, Inc. |
Medizinische verwendungen von immunzellenaktivierungsmodulierenden substanzen und entsprechende screeningverfahren
|
BR112015002681A2
(pt)
|
2012-08-07 |
2018-08-28 |
Genentech Inc |
método para tratar um paciente e kit
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
CN104755498B
(zh)
|
2012-08-31 |
2019-06-18 |
伊缪诺金公司 |
用于检测叶酸受体1的诊断测定和试剂盒
|
US9737493B2
(en)
|
2012-09-07 |
2017-08-22 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for modulating DNMT1 inhibitor activity
|
US9976180B2
(en)
|
2012-09-14 |
2018-05-22 |
Population Bio, Inc. |
Methods for detecting a genetic variation in subjects with parkinsonism
|
EP2900835A4
(de)
|
2012-09-27 |
2016-05-11 |
Population Diagnotics Inc |
Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
2つのFabフラグメントを含むFc不含抗体および使用方法
|
EP2906598A1
(de)
|
2012-10-09 |
2015-08-19 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54-antikörper und verfahren zur verwendung davon
|
CA2887682A1
(en)
|
2012-10-09 |
2014-04-17 |
Biogen Idec Ma Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
EP3679950A1
(de)
|
2012-10-12 |
2020-07-15 |
The Brigham and Women's Hospital, Inc. |
Verbesserung der immunreaktion
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストによる処置の方法およびモニタリング
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2014071282A1
(en)
|
2012-11-05 |
2014-05-08 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
JP6302476B2
(ja)
|
2012-11-08 |
2018-03-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Her3のベータヘアピンに結合するher3抗原結合タンパク質
|
CA2886987C
(en)
|
2012-11-08 |
2022-07-12 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
EP3461501A1
(de)
|
2012-11-13 |
2019-04-03 |
F. Hoffmann-La Roche AG |
Anti-hemagglutinin-antikörper und verfahren zur verwendung
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
LT2928923T
(lt)
|
2012-12-10 |
2020-02-25 |
Biogen Ma Inc. |
Anti-kraujo dendritinių ląstelių antigeno 2 antikūnai ir jų panaudojimas
|
KR20150119848A
(ko)
|
2012-12-21 |
2015-10-26 |
바이오얼라이언스 씨.브이. |
친수성 자기-희생 링커 및 그것의 포합체
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
EP2935332B1
(de)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antikörpern
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2948178A4
(de)
|
2013-01-25 |
2016-07-20 |
Thymon Llc |
Zusammensetzungen zur selektiven reduktion von zirkulierendem bioaktivem löslichem tnf und verfahren zur behandlung einer tnf-vermittelten erkrankung
|
AU2014212081A1
(en)
|
2013-02-04 |
2015-08-13 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
TR201908761T4
(tr)
|
2013-02-22 |
2019-07-22 |
Abbvie Stemcentrx Llc |
Antidll3-antikor-pbd konjugatları ve kullanımları.
|
MX2015010791A
(es)
|
2013-02-22 |
2015-11-26 |
Hoffmann La Roche |
Metodos para tratar el cancer y prevenir la resistencia a farmacos.
|
MX369175B
(es)
|
2013-02-25 |
2019-10-30 |
Genentech Inc |
Métodos para detectar mutantes de akt resistentes a fármacos.
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
WO2014138364A2
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
US20160017017A1
(en)
*
|
2013-03-11 |
2016-01-21 |
Novo Nordisk Healthcare Ag |
Growth Hormone Compounds
|
CN105229035A
(zh)
*
|
2013-03-11 |
2016-01-06 |
诺和诺德保健股份有限公司 |
生长激素化合物
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
RU2019137020A
(ru)
|
2013-03-13 |
2021-01-14 |
Дженентек, Инк. |
Составы со сниженным окислением
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
ES2688895T3
(es)
|
2013-03-13 |
2018-11-07 |
F. Hoffmann-La Roche Ag |
Formulaciones con oxidación reducida
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
EP3299391B1
(de)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
PE20151893A1
(es)
|
2013-03-14 |
2015-12-30 |
Parkash Gill |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
JP2016516046A
(ja)
|
2013-03-14 |
2016-06-02 |
ジェネンテック, インコーポレイテッド |
がんの治療方法及びがん薬物耐性を阻止する方法
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
CN105228649B
(zh)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
Hcv抗原-抗体组合测定和方法以及用在其中的组合物
|
SG11201504260UA
(en)
|
2013-03-14 |
2015-10-29 |
Abbvie Inc |
Low acidic species compositions and methods for producing and using the same
|
CN113549148A
(zh)
|
2013-03-14 |
2021-10-26 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EA038918B1
(ru)
|
2013-03-15 |
2021-11-09 |
Зинджения, Инк. |
Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
PL2970875T3
(pl)
|
2013-03-15 |
2020-08-10 |
F.Hoffmann-La Roche Ag |
Kompozycje do hodowli komórkowych z przeciwutleniaczami i sposoby wytwarzania polipeptydów
|
SG11201507432XA
(en)
|
2013-03-15 |
2015-10-29 |
Abbvie Inc |
Antibody drug conjugate (adc) purification
|
BR112015023120A2
(pt)
|
2013-03-15 |
2017-11-21 |
Genentech Inc |
método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
|
JP6387392B2
(ja)
|
2013-03-15 |
2018-09-05 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子ポリペプチド製剤
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
EP4079760A3
(de)
|
2013-03-15 |
2023-01-25 |
Sanofi Pasteur Inc. |
Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
|
AR095517A1
(es)
|
2013-03-15 |
2015-10-21 |
Genentech Inc |
ANTICUERPOS CONTRA EL RECEPTOR QUIMIOATRAYENTE EXPRESADO EN CÉLULAS T HELPER 2 (ANTI-CRTh2) Y MÉTODOS DE USO
|
HUE039291T2
(hu)
|
2013-03-15 |
2018-12-28 |
Hoffmann La Roche |
IL-22 polipeptidek és IL-22 FC fúziós fehérjék és alkalmazási eljárások
|
AU2014228172B2
(en)
|
2013-03-15 |
2018-12-06 |
Abbvie Deutschland Gmbh & Co.Kg |
Anti-EGFR antibody drug conjugate formulations
|
CA2904448A1
(en)
|
2013-03-15 |
2014-09-18 |
Tariq Ghayur |
Dual specific binding proteins directed against il-1.beta. and/or il-17
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
WO2014151866A1
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
ES2841123T3
(es)
|
2013-04-05 |
2021-07-07 |
Formulacion Del Compuesto De La Hormona De Crecimiento |
Formulación del compuesto de la hormona de crecimiento
|
CA2944989A1
(en)
|
2013-04-08 |
2014-10-16 |
Cytodyn Inc. |
Felinized antibodies and methods of treating retroviral infections in felines
|
MX2015015060A
(es)
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
|
MX364861B
(es)
|
2013-04-29 |
2019-05-09 |
Hoffmann La Roche |
Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares.
|
CN105143262A
(zh)
|
2013-04-29 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
结合人fcrn的修饰的抗体和使用方法
|
US10501802B2
(en)
|
2013-04-30 |
2019-12-10 |
Universite De Montreal |
Biomarkers for acute myeloid leukemia
|
WO2014182676A2
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
KR102293064B1
(ko)
|
2013-05-20 |
2021-08-23 |
제넨테크, 인크. |
항-트랜스페린 수용체 항체 및 사용 방법
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
EP3293275B1
(de)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
EP3003372B1
(de)
|
2013-06-07 |
2019-10-09 |
Duke University |
Inhibitoren des komplementfaktors h
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
EP3013365B1
(de)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2-antigene und verwendung davon
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
TWI685349B
(zh)
|
2013-07-16 |
2020-02-21 |
建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
CA2919477A1
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
TWI623551B
(zh)
|
2013-08-02 |
2018-05-11 |
輝瑞大藥廠 |
抗cxcr4抗體及抗體-藥物結合物
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
DK3036320T3
(da)
|
2013-08-19 |
2021-07-12 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
LT3041507T
(lt)
|
2013-08-26 |
2021-08-25 |
Biontech Research And Development, Inc. |
Nukleorūgštys, koduojančios antikūnus prieš sialil-lewis a
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
CN113150145A
(zh)
|
2013-08-30 |
2021-07-23 |
伊缪诺金公司 |
用于检测叶酸受体1的抗体和测定
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
EP3049521B1
(de)
|
2013-09-25 |
2019-03-06 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
EP3048899B1
(de)
|
2013-09-25 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Verfahren zur virusinaktivierung auf einer säule
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
KR102331663B1
(ko)
|
2013-09-27 |
2021-11-25 |
제넨테크, 인크. |
항-pdl1 항체 제제
|
WO2015044083A1
(en)
|
2013-09-27 |
2015-04-02 |
F. Hoffmann-La Roche Ag |
Thermus thermophilus slyd fkbp domain specific antibodies
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US20150132323A1
(en)
|
2013-10-08 |
2015-05-14 |
Immunogen, Inc. |
Anti-FOLR1 Immunoconjugate Dosing Regimens
|
EP3055328A1
(de)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4-hemmer und verfahren zur verwendung
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
SG11201603127WA
(en)
|
2013-10-23 |
2016-05-30 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders
|
JP2016536018A
(ja)
|
2013-10-28 |
2016-11-24 |
ドッツ テクノロジー コーポレイションDOTS Technology Corp. |
アレルゲン検出
|
US10980896B2
(en)
|
2013-10-29 |
2021-04-20 |
President And Fellows Of Harvard College |
Methods and compositions for inhibiting oxidative stress
|
US20160272674A1
(en)
|
2013-11-07 |
2016-09-22 |
Abbvie Inc. |
Isolation and purification of antibodies
|
DK3511422T3
(da)
|
2013-11-12 |
2023-02-06 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til diagnosticering, prognose og behandling af endometriose
|
EP3068903B1
(de)
|
2013-11-15 |
2019-02-13 |
Institut Pasteur |
Molekularer marker der resistenz von artemisinin gegen plasmodium falciparum
|
MY176237A
(en)
|
2013-11-21 |
2020-07-24 |
Hoffmann La Roche |
Anti-alpha-synuclein antibodies and methods of use
|
US10081679B2
(en)
|
2013-11-25 |
2018-09-25 |
Ccam Biotherapeutics Ltd. |
Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
|
WO2015085311A1
(en)
|
2013-12-07 |
2015-06-11 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
BR112016013514B1
(pt)
|
2013-12-13 |
2022-04-19 |
Stora Enso Oyj (Fi) |
Papelão de múltiplas camadas
|
EP3080164B1
(de)
|
2013-12-13 |
2019-01-16 |
Genentech, Inc. |
Anti-cd33-antikörper und immunkonjugate
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量(hmw)タウ種およびその用途
|
SG10201809385RA
(en)
|
2013-12-17 |
2018-11-29 |
Genentech Inc |
Anti-cd3 antibodies and methods of use
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
SG11201604875PA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
KR102630750B1
(ko)
|
2013-12-17 |
2024-01-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
JP2017500017A
(ja)
|
2013-12-20 |
2017-01-05 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
EP4043493A1
(de)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista-antikörper und -fragmente
|
MX2016008187A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP6521464B2
(ja)
|
2014-01-03 |
2019-05-29 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
EP3096797A1
(de)
|
2014-01-24 |
2016-11-30 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von anti-steap1-antikörpern und immunkonjugaten
|
SG11201606018UA
(en)
|
2014-01-24 |
2016-08-30 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
US11648335B2
(en)
|
2014-01-31 |
2023-05-16 |
Wake Forest University Health Sciences |
Organ/tissue decellularization, framework maintenance and recellularization
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3102197B1
(de)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
MX2016010237A
(es)
|
2014-02-08 |
2017-04-27 |
Genentech Inc |
Metodos de tratamiento de enfermedad de alzheimer.
|
EP3718563A1
(de)
|
2014-02-08 |
2020-10-07 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von morbus alzheimer
|
AU2015217572B2
(en)
|
2014-02-11 |
2020-10-15 |
Visterra, Inc. |
Antibody moleules to dengue virus and uses thereof
|
CA2936565C
(en)
|
2014-02-12 |
2020-08-11 |
Genentech, Inc. |
Anti-jagged1 antibodies and methods of use
|
EP3107576A4
(de)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen
|
CN106029693A
(zh)
|
2014-02-21 |
2016-10-12 |
豪夫迈·罗氏有限公司 |
抗il-13/il-17双特异性抗体及其用途
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
ES2897765T3
(es)
|
2014-03-14 |
2022-03-02 |
Hoffmann La Roche |
Procedimientos y composiciones para la secreción de polipéptidos heterólogos
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
BR112016018408A2
(pt)
|
2014-03-14 |
2017-12-26 |
Immutep Sas |
moléculas de anticorpo à lag-3 e usos das mesmas
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
EP3119431B1
(de)
|
2014-03-21 |
2024-01-24 |
Teva Pharmaceuticals International GmbH |
Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
|
WO2015148515A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
KR20160137599A
(ko)
|
2014-03-24 |
2016-11-30 |
제넨테크, 인크. |
C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
JP6666262B2
(ja)
|
2014-04-02 |
2020-03-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体の軽鎖誤対合を検出するための方法
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
HUE051676T2
(hu)
|
2014-04-08 |
2021-03-29 |
Boston Pharmaceuticals Inc |
Il-21-re specifikus kötõ molekulák és alkalmazásaik
|
CN106232139A
(zh)
|
2014-04-11 |
2016-12-14 |
免疫医疗有限责任公司 |
双特异性her2抗体
|
BR112016024319B1
(pt)
|
2014-04-18 |
2024-01-23 |
Acceleron Pharma Inc |
USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
SG11201608772UA
(en)
|
2014-04-27 |
2016-11-29 |
Ccam Biotherapeutics Ltd |
Humanized antibodies against ceacam1
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
LT3137114T
(lt)
|
2014-04-30 |
2021-03-25 |
Pfizer Inc. |
Anti-ptk7 antikūnų ir vaistų konjugatai
|
RU2020103811A
(ru)
|
2014-05-05 |
2020-02-18 |
Регенерон Фармасьютикалз, Инк. |
Гуманизированные животные по с5 и с3
|
DK3142689T3
(da)
|
2014-05-13 |
2021-02-15 |
Bavarian Nordic As |
Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3
|
EP3888690A3
(de)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
EP3146071B1
(de)
|
2014-05-23 |
2020-09-02 |
F. Hoffmann-La Roche AG |
Mit-biomarker und verfahren mit verwendung davon
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカAcademia Sinica |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2950440A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
EP3970747A3
(de)
|
2014-06-03 |
2022-10-05 |
XBiotech Inc. |
Zusammensetzungen und verfahren zur behandlung und verhinderung von staphylococcus-aureus-infektionen
|
AU2015271685B2
(en)
|
2014-06-04 |
2021-02-18 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
JP2017528418A
(ja)
|
2014-06-20 |
2017-09-28 |
バイオアライアンス コマンディテール フェンノートシャップ |
抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
NZ728041A
(en)
|
2014-07-10 |
2023-01-27 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington’s disease
|
MX2017000363A
(es)
|
2014-07-11 |
2017-04-27 |
Genentech Inc |
Inhibicion de la via de notch.
|
WO2016011052A1
(en)
|
2014-07-14 |
2016-01-21 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
MX2017000546A
(es)
|
2014-07-15 |
2017-03-08 |
Genentech Inc |
Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
FI3172232T3
(fi)
|
2014-07-17 |
2024-03-19 |
Novo Nordisk As |
TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
|
WO2016014576A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
JP6940406B2
(ja)
|
2014-07-25 |
2021-09-29 |
テラベクティTheravectys |
キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
|
WO2016020798A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
TWI719946B
(zh)
|
2014-08-19 |
2021-03-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
EP3188746A4
(de)
|
2014-09-05 |
2018-05-02 |
The Johns Hopkins University |
Capn9/capns2-aktivität als ziel für eine therapeutische strategie zur behandlung von myofibroblastendifferenzierung und assoziierten erkrankungen
|
WO2016036403A1
(en)
|
2014-09-05 |
2016-03-10 |
Population Diagnostics Inc. |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
BR112017004631A2
(pt)
|
2014-09-12 |
2018-01-30 |
Genentech, Inc. |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento, de inibição da proliferação de uma célula e de detecção de her2 humana e método para a detecção de um câncer
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
MX2017003121A
(es)
|
2014-09-15 |
2017-08-02 |
Genentech Inc |
Formulaciones de anticuerpos.
|
CN107001471B
(zh)
|
2014-09-16 |
2022-01-18 |
西福根有限公司 |
抗met抗体和组合物
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
WO2016044697A1
(en)
|
2014-09-19 |
2016-03-24 |
The Johns Hopkins University |
Biomarkers of cognitive dysfunction
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
EP3197492A1
(de)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Behandlung mit anti-pcsk9- antikörpern
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
PL3200822T3
(pl)
|
2014-09-30 |
2021-11-08 |
Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts |
Cząsteczki wiążące, zwłaszcza przeciwciała, które wiążą się z l1cam (cd171)
|
CN113956361A
(zh)
|
2014-10-01 |
2022-01-21 |
免疫医疗有限公司 |
替格瑞洛的抗体及其使用方法
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US11124822B2
(en)
|
2014-10-17 |
2021-09-21 |
Carnegie Mellon University |
Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes
|
US10920208B2
(en)
|
2014-10-22 |
2021-02-16 |
President And Fellows Of Harvard College |
Evolution of proteases
|
AU2015336946A1
(en)
|
2014-10-23 |
2017-04-13 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
PE20170950A1
(es)
|
2014-10-24 |
2017-07-13 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
|
DK3212233T3
(da)
|
2014-10-31 |
2020-07-27 |
Oncomed Pharm Inc |
Kombinationsterapi til behandling af sygdom
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
JP6875276B2
(ja)
|
2014-11-05 |
2021-05-19 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
NZ732156A
(en)
|
2014-11-05 |
2023-11-24 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
KR102544705B1
(ko)
|
2014-11-05 |
2023-06-15 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
CN107074966A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
CN107249631B
(zh)
|
2014-11-07 |
2021-11-23 |
十一生物治疗股份有限公司 |
改进的il-6抗体
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
KR20170080607A
(ko)
|
2014-11-10 |
2017-07-10 |
메디뮨 리미티드 |
Cd73에 특이적인 결합 분자 및 이의 용도
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
EP3789403A1
(de)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3218005B1
(de)
|
2014-11-12 |
2023-01-04 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
EP3218397B8
(de)
|
2014-11-14 |
2021-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralisierende antikörper gegen ebola virus glykoprotein und deren verwendung
|
JP2017537090A
(ja)
|
2014-11-17 |
2017-12-14 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びpd−1軸結合アンタゴニストを含む併用療法
|
CN107429075B
(zh)
|
2014-11-17 |
2022-11-01 |
卡内基梅隆大学 |
可激活的双组份光敏剂
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
KR20240024318A
(ko)
|
2014-11-20 |
2024-02-23 |
에프. 호프만-라 로슈 아게 |
T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
CN107108739B
(zh)
|
2014-12-05 |
2022-01-04 |
豪夫迈·罗氏有限公司 |
抗CD79b抗体和使用方法
|
CN107206088A
(zh)
|
2014-12-05 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
|
BR112017011234A2
(pt)
|
2014-12-10 |
2018-03-27 |
Genentech Inc |
anticorpos contra receptor da barreira hematoencefálica e métodos de uso
|
PT3800202T
(pt)
|
2014-12-11 |
2023-01-05 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
EP3237450B1
(de)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk-antikörper und verwendungen davon
|
EP3237906B8
(de)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
AU2016206191B2
(en)
|
2015-01-09 |
2017-08-03 |
Adalta Limited |
CXCR4 binding molecules
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
WO2016118191A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
EP3250609A4
(de)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra-alpha-2-bindende wirkstoffe und verwendung davon bei der krebsbehandlung
|
EP3250611B1
(de)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car-t-zellen zur erkennung krebsspezifischer il 13r-alpha2
|
CA2973886A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102590740B1
(ko)
|
2015-02-02 |
2023-10-18 |
칠드런스 헬스 케어 디/비/에이 칠드런스 미네소타 |
항-대리 경쇄 항체
|
DK3253875T3
(da)
|
2015-02-04 |
2020-04-14 |
H Hoffmann La Roche Ag |
Tau-antisense-oligomerer og anvendelser deraf
|
US11761951B2
(en)
|
2015-02-04 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN114773469A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
LT3271389T
(lt)
|
2015-03-20 |
2020-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizuojantys antikūnai prieš gp120 ir jų panaudojimas
|
MA53297A
(fr)
|
2015-03-23 |
2022-05-04 |
Jounce Therapeutics Inc |
Anticorps anti-icos
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3273974A4
(de)
|
2015-03-26 |
2018-11-07 |
Women and Infants Hospital of Rhode Island Inc. |
Therapie für maligne erkrankungen
|
CN107530427A
(zh)
|
2015-03-27 |
2018-01-02 |
南加利福尼亚大学 |
针对用于实体肿瘤的治疗的lhr的car t细胞疗法
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
MY186708A
(en)
|
2015-04-03 |
2021-08-11 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
MA54328A
(fr)
|
2015-04-06 |
2021-10-06 |
Acceleron Pharma Inc |
Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
|
EP4249916A3
(de)
|
2015-04-06 |
2023-11-01 |
President and Fellows of Harvard College |
Zusammensetzungen und verfahren zur nicht-myeloablativen konditionierung
|
DK3280441T3
(da)
|
2015-04-07 |
2021-11-15 |
Alector Llc |
Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
CN107980046B
(zh)
|
2015-04-13 |
2021-12-24 |
辉瑞公司 |
靶向b细胞成熟抗原的嵌合抗原受体
|
KR102405104B1
(ko)
|
2015-04-13 |
2022-06-07 |
화이자 인코포레이티드 |
치료 항체 및 그의 용도
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
LT3283508T
(lt)
|
2015-04-17 |
2021-07-12 |
Alpine Immune Sciences, Inc. |
Imunomoduliuojantys baltymai su sureguliuojamu giminingumu
|
EP3285811A1
(de)
|
2015-04-21 |
2018-02-28 |
Institut Gustave Roussy |
Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
AU2016256486B2
(en)
|
2015-04-29 |
2021-09-23 |
University Of South Australia |
Compositions and methods for administering antibodies
|
EP3778640A1
(de)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Maskierte anti-cd3-antikörper und verfahren zur verwendung
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
US10844122B2
(en)
|
2015-05-06 |
2020-11-24 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
|
JP6867955B2
(ja)
|
2015-05-07 |
2021-05-12 |
アジェナス インコーポレイテッド |
抗ox40抗体及びその使用方法
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3294334B1
(de)
|
2015-05-11 |
2020-07-08 |
The Johns Hopkins University |
Autoimmunantikörper zur verwendung bei der hemmung des wachstums von krebszellen
|
DK3294770T3
(da)
|
2015-05-12 |
2020-12-07 |
Hoffmann La Roche |
Terapeutiske og diagnostiske fremgangsmåder til cancer
|
EP4209228A1
(de)
|
2015-05-22 |
2023-07-12 |
Translational Drug Development, LLC |
Benzamid- und wirkstoffzusammensetzungen sowie verfahren zur verwendung
|
CA2987146A1
(en)
|
2015-05-27 |
2016-12-01 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
PE20180672A1
(es)
|
2015-05-29 |
2018-04-19 |
Agenus Inc |
Anticuerpos anti-ctla-4 y metodos de uso de los mismos
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
RS59935B1
(sr)
|
2015-05-29 |
2020-03-31 |
Abbvie Inc |
Anti-cd40 antitela i njihove upotrebe
|
WO2016193380A1
(en)
|
2015-06-02 |
2016-12-08 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
EP3302552A1
(de)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Zusammensetzungen und verfahren zur verwendung von anti-il-34-antikörpern zur behandlung von neurologischen erkrankungen
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2016197064A1
(en)
|
2015-06-04 |
2016-12-08 |
Epstein Alan L |
Lym-1 and lym-2 targeted car cell immunotherapy
|
TWI790642B
(zh)
|
2015-06-05 |
2023-01-21 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
JP2018518491A
(ja)
|
2015-06-12 |
2018-07-12 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
SG10201912085WA
(en)
|
2015-06-12 |
2020-02-27 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
CN114507289A
(zh)
|
2015-06-16 |
2022-05-17 |
豪夫迈·罗氏有限公司 |
人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
CN107787331B
(zh)
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗her2抗体和使用方法
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
JP7026509B2
(ja)
|
2015-06-24 |
2022-02-28 |
ヤンセン ファーマシューティカ エヌブイ |
抗vista抗体およびフラグメント
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
WO2017004026A1
(en)
|
2015-06-29 |
2017-01-05 |
Immunogen, Inc. |
Anti-cd 123 antibodies and conjugates and derivatives thereof
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
US10392674B2
(en)
|
2015-07-22 |
2019-08-27 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
WO2017015559A2
(en)
|
2015-07-23 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of bt toxins
|
EP3316902A1
(de)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
CN108348578B
(zh)
|
2015-08-04 |
2022-08-09 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3932953A1
(de)
|
2015-08-28 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Anti-hypusin-antikörper und verwendungen davon
|
WO2017040790A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
AU2016323447B2
(en)
|
2015-09-15 |
2023-03-30 |
Scholar Rock, Inc. |
Anti-pro/latent-Myostatin antibodies and uses thereof
|
CA2994888A1
(en)
|
2015-09-17 |
2017-03-23 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-folr1 immunoconjugates
|
WO2017046994A1
(en)
|
2015-09-18 |
2017-03-23 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
EP3569244A1
(de)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3-gerichtete car-zellen zur immuntherapie
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
CA2999160A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
CN108289954B
(zh)
|
2015-09-24 |
2022-05-31 |
阿布维特罗有限责任公司 |
Hiv抗体组合物和使用方法
|
CN108289953B
(zh)
|
2015-09-29 |
2022-03-11 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
US20180282415A1
(en)
|
2015-09-30 |
2018-10-04 |
Merck Patent Gmbh |
Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
BR112018005164A2
(pt)
|
2015-10-02 |
2019-10-01 |
Hoffmann La Roche |
anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
WO2017070608A1
(en)
|
2015-10-23 |
2017-04-27 |
Eureka Therapeutics, Inc. |
Antibody/t-cell receptor chimeric constructs and uses thereof
|
AU2016347471B2
(en)
|
2015-10-27 |
2023-08-03 |
UCB Biopharma SRL |
Methods of treatment using anti-IL-17A/F antibodies
|
EP3368566A1
(de)
|
2015-10-28 |
2018-09-05 |
Friedrich Miescher Institute for Biomedical Research |
Tenascin-w und gallengangkrebs
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
CA3002676A1
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
SI3368578T1
(sl)
|
2015-10-30 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Protitelesa proti HtrA1 in postopki uporabe
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
GB201519303D0
(en)
*
|
2015-11-02 |
2015-12-16 |
Imp Innovations Ltd |
Phagemid vector
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
CN108602884A
(zh)
|
2015-11-08 |
2018-09-28 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
WO2017083451A1
(en)
|
2015-11-10 |
2017-05-18 |
Medimmune, Llc |
Binding molecules specific for asct2 and uses thereof
|
JP7041628B2
(ja)
|
2015-11-10 |
2022-03-24 |
ビステラ, インコーポレイテッド |
リポ多糖に特異的に結合する抗体分子-薬物コンジュゲートおよびその使用
|
MX2018005061A
(es)
|
2015-11-12 |
2019-02-28 |
Siamab Therapeutics Inc |
Compuestos de interacción con glicanos y métodos de uso.
|
WO2017091706A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
PL3380522T3
(pl)
|
2015-11-25 |
2024-03-25 |
Visterra, Inc. |
Cząsteczki przeciwciał wobec april i ich zastosowania
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
TWI597292B
(zh)
|
2015-12-18 |
2017-09-01 |
中外製藥股份有限公司 |
抗c5抗體及使用方法
|
WO2017112956A1
(en)
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
WO2017118307A1
(zh)
|
2016-01-05 |
2017-07-13 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
EP3400240A2
(de)
|
2016-01-08 |
2018-11-14 |
Scholar Rock, Inc. |
Anti-pro/latente myostatin-antikörper und verfahren zur verwendung davon
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
JP7078536B2
(ja)
|
2016-01-08 |
2022-05-31 |
アルトゥルバイオ, インコーポレイテッド |
四価抗psgl-1抗体とその使用
|
CA3011739A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
EP3405481B1
(de)
|
2016-01-21 |
2023-01-18 |
Pfizer Inc. |
Chimäre antigenrezeptoren mit abzielung auf den epidermalen wachstumsfaktorrezeptor variante iii
|
TWI657096B
(zh)
|
2016-01-21 |
2019-04-21 |
輝瑞股份有限公司 |
對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
EP3413910A1
(de)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5)-antikörper
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
MX2018010361A
(es)
|
2016-02-29 |
2019-07-08 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
SG11201807523PA
(en)
|
2016-03-10 |
2018-09-27 |
Viela Bio Inc |
Ilt7 binding molecules and methods of using the same
|
JP6987072B2
(ja)
|
2016-03-10 |
2021-12-22 |
アクセレロン ファーマ インコーポレーテッド |
アクチビン2型受容体結合タンパク質及びその使用
|
PL3365368T3
(pl)
|
2016-03-11 |
2023-08-21 |
Scholar Rock, Inc. |
Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
EP3430054B1
(de)
|
2016-03-15 |
2021-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und anti-gpc3-antikörpern
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
KR20180138205A
(ko)
|
2016-03-22 |
2018-12-28 |
바이오노믹스 리미티드 |
항-lgr5 단클론성 항체의 투여
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
TW202302144A
(zh)
|
2016-03-25 |
2023-01-16 |
美商威特拉公司 |
登革病毒的抗體分子之配方設計
|
KR20240034883A
(ko)
|
2016-03-29 |
2024-03-14 |
얀센 바이오테크 인코포레이티드 |
항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
|
WO2017172990A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
KR102486507B1
(ko)
|
2016-04-08 |
2023-01-09 |
아이티아이 헬스, 인크. |
플렉틴-1 결합 항체 및 그의 용도
|
EP3443004A1
(de)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3-antikörper und verfahren zur verwendung
|
EP3443350B1
(de)
|
2016-04-15 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
EP3443120A2
(de)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
US20170298119A1
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
EP3448881B1
(de)
|
2016-04-26 |
2023-06-07 |
Icahn School of Medicine at Mount Sinai |
Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
WO2017200981A1
(en)
|
2016-05-16 |
2017-11-23 |
Baxalta Incorporated |
Anti-factor ix padua antibodies
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
WO2017205465A2
(en)
|
2016-05-24 |
2017-11-30 |
Griswold Karl Edwin |
Antibodies and methods of making same
|
MX2018014387A
(es)
|
2016-05-27 |
2019-03-14 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
EP3465221B1
(de)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
CN109476699B
(zh)
|
2016-06-02 |
2021-10-12 |
艾伯维公司 |
糖皮质激素受体激动剂及其免疫偶联物
|
EP3464280B1
(de)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
|
EP3464345A1
(de)
|
2016-06-06 |
2019-04-10 |
F. Hoffmann-La Roche AG |
Fusionsproteine für die ophthalmologie mit erhöhter augenretention
|
CN116143918A
(zh)
|
2016-06-24 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
EP3478717B1
(de)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Neuartiges antikörperformat
|
US11292801B2
(en)
|
2016-07-05 |
2022-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
EP3484512A1
(de)
|
2016-07-13 |
2019-05-22 |
Biogen MA Inc. |
Dosierungspläne von lingo-1-antagonisten und verwendung zur behandlung von demyelinisierungserkrankungen
|
AU2017296237A1
(en)
|
2016-07-15 |
2019-01-03 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
|
WO2018014038A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
HUE054228T2
(hu)
|
2016-07-15 |
2021-08-30 |
Acceleron Pharma Inc |
Használható actriia polipeptideket tartalmazó összetételek a pulmonalis hypertónia kezelésében történõ alkalmazásra
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
CN109415444B
(zh)
|
2016-07-29 |
2024-03-01 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
US10519250B2
(en)
|
2016-08-01 |
2019-12-31 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
|
US11858980B2
(en)
|
2016-08-02 |
2024-01-02 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
WO2018027042A1
(en)
|
2016-08-03 |
2018-02-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
WO2018027124A1
(en)
|
2016-08-05 |
2018-02-08 |
Medimmune, Llc |
Anti-o2 antibodies and uses thereof
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
AU2017316663B2
(en)
|
2016-08-22 |
2024-02-22 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
MX2019002867A
(es)
|
2016-09-19 |
2019-11-12 |
Celgene Corp |
Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
|
US10766958B2
(en)
|
2016-09-19 |
2020-09-08 |
Celgene Corporation |
Methods of treating vitiligo using PD-1 binding antibodies
|
EP3515936A1
(de)
|
2016-09-23 |
2019-07-31 |
Elstar Therapeutics, Inc. |
Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
|
WO2018055574A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating refractory migraine
|
EA201990548A1
(ru)
|
2016-09-23 |
2019-09-30 |
Тева Фармасьютикалз Интернэшнл Гмбх |
Лечение кластерной головной боли
|
SG11201900845YA
(en)
|
2016-09-23 |
2019-02-27 |
Genentech Inc |
Uses of il-13 antagonists for treating atopic dermatitis
|
CN110087681A
(zh)
|
2016-09-28 |
2019-08-02 |
佐马美国有限公司 |
结合白细胞介素-2的抗体和其用途
|
JP2020500207A
(ja)
|
2016-09-28 |
2020-01-09 |
ブレード・セラピューティクス・インコーポレイテッド |
カルパインモジュレーター及びそれらの治療上の使用
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
MA46366A
(fr)
|
2016-09-30 |
2019-08-07 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
JP2019530875A
(ja)
|
2016-10-03 |
2019-10-24 |
アボット・ラボラトリーズAbbott Laboratories |
患者サンプルにおけるuch−l1状況を評価する改善された方法
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
WO2018068028A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
AU2017343621B2
(en)
|
2016-10-11 |
2021-12-02 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
EP3529273A4
(de)
|
2016-10-19 |
2020-07-01 |
Medlmmune, LLC |
Anti-o1-antikörper und verwendungen davon
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
US11249082B2
(en)
|
2016-10-29 |
2022-02-15 |
University Of Miami |
Zika virus assay systems
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
WO2018085359A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
WO2018093841A1
(en)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-il-23 specific antibody
|
EP3541847A4
(de)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
WO2018098401A1
(en)
|
2016-11-23 |
2018-05-31 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
WO2018098363A2
(en)
|
2016-11-23 |
2018-05-31 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
EP3551225A1
(de)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antikörper und verfahren zur verwendung davon
|
SI3551660T1
(sl)
|
2016-12-07 |
2024-02-29 |
Agenus Inc. |
Protitelesa proti antictla-4 in načini njihove uporabe
|
AU2017373889A1
(en)
|
2016-12-07 |
2019-06-06 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
WO2018114878A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
CN110088292A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
MX2019006266A
(es)
|
2016-12-21 |
2019-08-21 |
Hoffmann La Roche |
Glucomanipulacion in vitro de anticuerpos.
|
JP7360324B2
(ja)
|
2016-12-23 |
2023-10-12 |
ビステラ, インコーポレイテッド |
結合ポリペプチドおよびそれを作製する方法
|
JP7157744B2
(ja)
|
2017-01-06 |
2022-10-20 |
スカラー ロック インコーポレイテッド |
アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
|
PL3565592T3
(pl)
|
2017-01-06 |
2023-08-21 |
Scholar Rock, Inc. |
Leczenie chorób metabolicznych poprzez inhibicję aktywacji miostatyny
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
EP3568468A4
(de)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
Gegen histon-h3-peptid/mhc-komplexe gerichtete konstrukte und verwendungen davon
|
TWI659750B
(zh)
|
2017-01-13 |
2019-05-21 |
中央研究院 |
用以治療心肌梗塞之可重複裝載之改良水膠系統
|
WO2018130661A1
(en)
|
2017-01-13 |
2018-07-19 |
Academia Sinica |
Reloadable hydrogel system for treating brain conditions
|
US11890319B2
(en)
|
2017-01-18 |
2024-02-06 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
AU2018214451B2
(en)
|
2017-02-06 |
2022-02-03 |
Meat & Livestock Australia Limited |
Immunostimulating compositions and uses therefore
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
EP3580235A1
(de)
|
2017-02-10 |
2019-12-18 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
SG10202111663PA
(en)
|
2017-02-27 |
2021-12-30 |
Regeneron Pharma |
Humanized model of kidney and liver disorders
|
AU2018228873A1
(en)
|
2017-03-01 |
2019-08-29 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2018160897A1
(en)
|
2017-03-02 |
2018-09-07 |
Beth Israel Deaconess Medical Center, Inc. |
Preventing post-ictal headaches
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
BR112019018043A2
(pt)
|
2017-03-03 |
2020-04-07 |
Seattle Genetics Inc |
método de tratamento de câncer, e, conjugado de anticorpo-fármaco
|
JP7206227B2
(ja)
|
2017-03-13 |
2023-01-17 |
ポセイダ セラピューティクス,インコーポレイティド |
造血幹細胞の選択的除去と置換のための組成物と方法
|
MA49265A
(fr)
|
2017-03-22 |
2020-02-05 |
Ascendis Pharma As |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
CR20190481A
(es)
|
2017-03-22 |
2020-01-06 |
Genentech Inc |
Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
JP2020514394A
(ja)
|
2017-03-24 |
2020-05-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
異常な線維芽細胞におけるプロテオグリカンの不規則性及びそれに基づく治療法
|
BR112019017629A2
(pt)
|
2017-03-27 |
2020-04-07 |
Hoffmann La Roche |
receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
BR112019017329A2
(pt)
|
2017-04-03 |
2020-04-14 |
Hoffmann La Roche |
imunoconjugados, um ou mais polinucleotídeos e vetores, métodos para a produção de um imunoconjugado, tratamento de uma doença e para a estimulação do sistema imunológico, composição, uso do imunoconjugado, invenção e usos da composição
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
EP3606963B1
(de)
|
2017-04-03 |
2023-08-30 |
F. Hoffmann-La Roche AG |
An steap-1 bindende antikörper
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
KR102294136B1
(ko)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー/エス |
オリゴマー伸長インスリン−Fcコンジュゲート
|
KR102408873B1
(ko)
|
2017-04-05 |
2022-06-15 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
WO2018189611A1
(en)
|
2017-04-12 |
2018-10-18 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
BR112019021472A8
(pt)
|
2017-04-14 |
2023-05-02 |
Inst Curie |
Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
|
US20230227566A1
(en)
|
2017-04-14 |
2023-07-20 |
Gamamabs Pharma |
Amhrii-binding compounds for preventing or treating lung cancers
|
CN110546513A
(zh)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
|
CN110709422B
(zh)
|
2017-04-19 |
2023-12-26 |
马伦戈治疗公司 |
多特异性分子及其用途
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
GB201706451D0
(en)
*
|
2017-04-24 |
2017-06-07 |
Imp Innovations Ltd |
Cancer treatment
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
JP7295030B2
(ja)
|
2017-04-26 |
2023-06-20 |
ユーリカ セラピューティックス, インコーポレイテッド |
グリピカン3を特異的に認識するコンストラクト及びその使用
|
CN110662547A
(zh)
|
2017-04-26 |
2020-01-07 |
优瑞科生物技术公司 |
表达嵌合活化受体及嵌合刺激受体的细胞及其用途
|
TWI791519B
(zh)
|
2017-04-27 |
2023-02-11 |
美商提薩羅有限公司 |
針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
EP3635407A1
(de)
|
2017-04-28 |
2020-04-15 |
Abbott Laboratories |
Verfahren zur unterstützung der hyperakuten diagnose und bestimmung von traumatischer hirnverletzung unter verwendung von frühbiomarkern auf mindestens zwei proben aus dem gleichen menschlichen patienten
|
HRP20230941T1
(hr)
|
2017-05-01 |
2023-11-24 |
Agenus Inc. |
Anti-tigit antitijela i postupci njihove primjene
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
WO2018215535A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
AU2018275235A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
CN110831970A
(zh)
|
2017-06-02 |
2020-02-21 |
辉瑞公司 |
靶向flt3的嵌合抗原受体
|
PE20191846A1
(es)
|
2017-06-02 |
2019-12-31 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
US11572541B2
(en)
|
2017-06-09 |
2023-02-07 |
Providence Health & Services—Oregon |
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3641752A4
(de)
|
2017-06-22 |
2021-03-17 |
Moonshot Pharma LLC |
Verfahren zur behandlung von krebs mit zusammensetzungen mit amlexanox und immunmodulatoren
|
CN110944666A
(zh)
|
2017-06-26 |
2020-03-31 |
博奥泰克尼公司 |
杂交瘤克隆、vsig-4的单克隆抗体,以及制备和使用的方法
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
WO2019010131A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
|
WO2019010164A1
(en)
|
2017-07-06 |
2019-01-10 |
President And Fellows Of Harvard College |
EVOLUTION OF ARNT SYNTHÉTASES
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
CN111032694B
(zh)
|
2017-07-14 |
2024-03-08 |
辉瑞大药厂 |
针对madcam的抗体
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
US20190048073A1
(en)
|
2017-07-20 |
2019-02-14 |
Pfizer Inc. |
Anti-gd3 antibodies and antibody-drug conjugates
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
US20200231682A1
(en)
|
2017-07-28 |
2020-07-23 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
JP7299160B2
(ja)
|
2017-08-03 |
2023-06-27 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
AU2018311079B2
(en)
|
2017-08-03 |
2022-06-23 |
Amgen Inc. |
Interleukin-21 muteins and methods of treatment
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
EP3684811A2
(de)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
|
EP3672990A1
(de)
|
2017-08-25 |
2020-07-01 |
Five Prime Therapeutics, Inc. |
B7-h4-antikörper und verfahren zur verwendung davon
|
WO2019051424A2
(en)
|
2017-09-08 |
2019-03-14 |
Poseida Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
KR20200049764A
(ko)
|
2017-09-29 |
2020-05-08 |
추가이 세이야쿠 가부시키가이샤 |
혈액 응고 제 viii 인자(fviii) 보인자 기능 대체 활성을 갖는 다중특이성 항원 결합 분자 및 당해 분자를 유효 성분으로서 함유하는 약학적 제제
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
AU2018345637A1
(en)
|
2017-10-02 |
2020-03-05 |
Visterra, Inc. |
Antibody molecules to CD138 and uses thereof
|
KR20210027230A
(ko)
|
2017-10-04 |
2021-03-10 |
옵코 파마슈티칼스, 엘엘씨 |
암의 개인 맞춤형 치료에 관한 물품 및 방법
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
CA3078155A1
(en)
|
2017-10-19 |
2019-04-25 |
Debiopharm International S.A. |
Combination product for the treatment of cancer
|
EP3697809A1
(de)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Für rush angepasste dap10/12-basierte cars
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
CA3079747A1
(en)
|
2017-10-31 |
2019-05-09 |
Allogene Therapeutics, Inc. |
Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
JP7039694B2
(ja)
|
2017-10-31 |
2022-03-22 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
EP3704146B1
(de)
|
2017-11-01 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Trifab-contorsbody
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
CA3082365A1
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019102435A1
(en)
|
2017-11-27 |
2019-05-31 |
Euro-Celtique S.A. |
Humanized antibodies targeting human tissue factor
|
WO2019108755A1
(en)
|
2017-11-30 |
2019-06-06 |
Genentech, Inc. |
Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
|
WO2019113464A1
(en)
|
2017-12-08 |
2019-06-13 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
EP3721234A1
(de)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
|
CN111094983A
(zh)
|
2017-12-09 |
2020-05-01 |
雅培实验室 |
使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
JP7394058B2
(ja)
|
2017-12-21 |
2023-12-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
|
CN111527107A
(zh)
|
2017-12-21 |
2020-08-11 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
WO2019122060A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Car-t cell assay for specificity test of novel antigen binding moieties
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
WO2019126514A2
(en)
|
2017-12-22 |
2019-06-27 |
Jounce Therapeutics, Inc. |
Antibodies for lilrb2
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
TW201930358A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對tigit之單域抗體及其變異體
|
JP2021508498A
(ja)
|
2017-12-29 |
2021-03-11 |
アレクター リミテッド ライアビリティ カンパニー |
抗tmem106b抗体及びその使用方法
|
BR112020013144A2
(pt)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer
|
EP3737694B1
(de)
|
2018-01-12 |
2023-03-01 |
Amgen Inc. |
Anti-pd-1-antikörper und behandlungsverfahren
|
KR20200120641A
(ko)
|
2018-01-15 |
2020-10-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
EP3740505A1
(de)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
|
EP3746476A1
(de)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a-antikörper und verfahren zu ihrer verwendung
|
KR20200115596A
(ko)
|
2018-02-01 |
2020-10-07 |
화이자 인코포레이티드 |
Cd70에 특이적인 항체 및 이의 용도
|
KR20200128018A
(ko)
|
2018-02-01 |
2020-11-11 |
화이자 인코포레이티드 |
Cd70을 표적으로 하는 키메라 항원 수용체
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
CN111868082A
(zh)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
调节vista和vsig3的相互作用的化合物及其制备和使用方法
|
EP3749678A1
(de)
|
2018-02-07 |
2020-12-16 |
Dana Farber Cancer Institute, Inc. |
Zellpermeable, geheftete peptidmodule zur zellulären abgabe
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019157358A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
US11512127B2
(en)
|
2018-02-14 |
2022-11-29 |
Viela Bio, Inc. |
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
JP2021514648A
(ja)
|
2018-03-01 |
2021-06-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の標的抗原結合部分のための特異性アッセイ
|
MA52416A
(fr)
|
2018-03-02 |
2021-04-21 |
Five Prime Therapeutics Inc |
Anticorps b7-h4 et leurs procédés d'utilisation
|
KR20200129125A
(ko)
|
2018-03-05 |
2020-11-17 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
US10982002B2
(en)
|
2018-03-12 |
2021-04-20 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
MX2021015518A
(es)
|
2018-03-14 |
2022-07-21 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos.
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
KR20210005007A
(ko)
|
2018-03-22 |
2021-01-13 |
서피스 온콜로지, 인크. |
항-il-27 항체 및 이의 용도
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
SI3775909T1
(sl)
|
2018-03-26 |
2023-10-30 |
Glycanostics S.R.O. |
Sredstva in postopki za glikoprofiliranje proteina
|
EP3775900A1
(de)
|
2018-03-26 |
2021-02-17 |
Alexion Pharmaceuticals, Inc. |
Hochdurchsatzverfahren zur messung der proteaseaktivität von komplement-c3-konvertase
|
SG11202009625WA
(en)
|
2018-04-02 |
2020-10-29 |
Bristol Myers Squibb Co |
Anti-trem-1 antibodies and uses thereof
|
EP3778639A4
(de)
|
2018-04-02 |
2021-06-09 |
Mab-Venture Biopharm Co., Ltd. |
Lymphozytenantigen-3 (lag-3)-bindender antikörper und seine verwendung
|
EP3775883A1
(de)
|
2018-04-04 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Diagnostische assays zum nachweis von tumorantigenen bei krebspatienten
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
WO2019207159A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
JP7411575B2
(ja)
|
2018-05-11 |
2024-01-11 |
ウーシー・バイオロジクス・(シャンハイ)・カンパニー・リミテッド |
Ox40に対する完全ヒト抗体、それを調製する方法、およびその使用
|
WO2019215701A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of treating depression using il-23 antibodies
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
US20200109195A1
(en)
|
2018-05-21 |
2020-04-09 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
PE20210127A1
(es)
|
2018-05-23 |
2021-01-19 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
EA202092825A1
(ru)
|
2018-05-25 |
2021-04-22 |
ЭЛЕКТОР ЭлЭлСи |
Анти-sirpa антитела и способы их применения
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
US11830582B2
(en)
|
2018-06-14 |
2023-11-28 |
University Of Miami |
Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
|
EP3806898A1
(de)
|
2018-06-18 |
2021-04-21 |
UCB Biopharma SRL |
Gremlin-1-antagonist zur vorbeugung und behandlung von krebs
|
WO2019245817A1
(en)
|
2018-06-19 |
2019-12-26 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
BR112020026033A2
(pt)
|
2018-06-19 |
2021-03-23 |
Atarga, Llc |
moléculas de anticorpo para complementar o componente 5 e usos das mesmas
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
KR20210024550A
(ko)
|
2018-06-23 |
2021-03-05 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
EA202190138A1
(ru)
|
2018-06-29 |
2021-05-27 |
ЭЛЕКТОР ЭлЭлСи |
Анти-sirp-бета1 антитела и способы их использования
|
EP3818083A2
(de)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr-antikörpermoleküle und ihre verwendungen
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
EP4019046A1
(de)
|
2018-07-11 |
2022-06-29 |
Scholar Rock, Inc. |
Isoformselektive tgfbeta1-inhibitoren und verwendung davon
|
CA3105988A1
(en)
|
2018-07-11 |
2020-01-16 |
Abhishek Datta |
High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
|
TW202019957A
(zh)
|
2018-07-11 |
2020-06-01 |
美商供石公司 |
TGFβ1抑制劑及其用途
|
KR20230065382A
(ko)
|
2018-07-13 |
2023-05-11 |
알렉터 엘엘씨 |
항-소틸린 항체 및 이들의 사용 방법
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
EP3824295A4
(de)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
Prädiktoren mit verzögerter wirkung nach behandlung mit anti-il23-spezifischem antikörper
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
SG11202100601TA
(en)
|
2018-08-08 |
2021-02-25 |
Genentech Inc |
Use of tryptophan derivatives and l-methionine for protein formulation
|
CA3108807A1
(en)
|
2018-08-08 |
2020-02-13 |
Pml Screening, Llc |
Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
EP3833442A2
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antikörper zur bindung von cd277 und verwendungen davon
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
AU2019318031A1
(en)
|
2018-08-10 |
2021-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CD137 antigen-binding molecule and utilization thereof
|
CA3109209A1
(en)
|
2018-08-10 |
2020-02-13 |
Eutilex Co., Ltd. |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
TW202016307A
(zh)
|
2018-08-31 |
2020-05-01 |
美商阿列克特有限責任公司 |
抗cd33 抗體及其使用方法
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
WO2020061349A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
FI13575Y1
(fi)
|
2018-09-24 |
2024-03-26 |
Janssen Biotech Inc |
IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi
|
WO2020069372A1
(en)
|
2018-09-27 |
2020-04-02 |
Elstar Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
TW202019958A
(zh)
|
2018-09-28 |
2020-06-01 |
日商協和麒麟股份有限公司 |
Il-36抗體及其用途
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
CA3113818A1
(en)
|
2018-10-05 |
2020-04-09 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
JP7289913B2
(ja)
|
2018-10-11 |
2023-06-12 |
ファイザー・インク |
Tfpiアンタゴニストのための投薬レジメン
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
EP3867646A1
(de)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
|
US20210380669A1
(en)
|
2018-10-23 |
2021-12-09 |
Scholar Rock, Inc. |
Rgmc-selective inhibitors and use thereof
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
CA3117051A1
(en)
|
2018-11-05 |
2020-05-14 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
US20210403597A1
(en)
|
2018-11-16 |
2021-12-30 |
Memorial Sloan Kettering Cancer Center |
Antibodies to mucin-16 and methods of use thereof
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
EP3883961A1
(de)
|
2018-11-20 |
2021-09-29 |
Takeda Vaccines, Inc. |
Neuartige zika-virus-antikörper und ihre verwendungen
|
BR112021009856A8
(pt)
|
2018-11-20 |
2021-09-08 |
Bavarian Nordic As |
Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
CA3119798A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
JP2022514561A
(ja)
|
2018-12-18 |
2022-02-14 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体でループスを治療する安全かつ有効な方法
|
CN113227131A
(zh)
|
2018-12-20 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
JP2022513507A
(ja)
|
2018-12-20 |
2022-02-08 |
ポセイダ セラピューティクス,インコーポレイティド |
ナノトランスポゾン組成物および使用方法
|
US20220289857A1
(en)
|
2018-12-20 |
2022-09-15 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
WO2020132214A2
(en)
|
2018-12-20 |
2020-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
JP2022514017A
(ja)
|
2018-12-20 |
2022-02-09 |
ノバルティス アーゲー |
医薬の組み合わせ
|
MX2021007421A
(es)
|
2018-12-21 |
2021-08-05 |
Hoffmann La Roche |
Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.
|
EP3898984A1
(de)
|
2018-12-21 |
2021-10-27 |
Genentech, Inc. |
Verfahren zur herstellung von polypeptiden unter verwendung einer gegen apoptose resistenten zelllinie
|
WO2020136060A1
(en)
|
2018-12-28 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
CN113227135A
(zh)
|
2018-12-28 |
2021-08-06 |
斯帕克斯治疗公司 |
用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
|
EP3911676A1
(de)
|
2019-01-15 |
2021-11-24 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von juveniler idiopathischer arthritis
|
SG11202107538VA
(en)
|
2019-01-16 |
2021-08-30 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
KR20210118878A
(ko)
|
2019-01-23 |
2021-10-01 |
얀센 바이오테크 인코포레이티드 |
건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
|
CA3124515A1
(en)
|
2019-01-23 |
2020-07-30 |
Genentech, Inc. |
Methods of producing multimeric proteins in eukaryotic host cells
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
JP2022518796A
(ja)
|
2019-01-28 |
2022-03-16 |
メイプル バイオテック エルエルシー |
肺、腎臓、または肝臓の線維症疾患の処置に使用するためのpsmpアンタゴニスト
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
TW202043267A
(zh)
|
2019-01-30 |
2020-12-01 |
美商供石公司 |
TGFβ之LTBP複合物專一性抑制劑及其用途
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3696191A1
(de)
|
2019-02-14 |
2020-08-19 |
Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) |
Car-t-zellen zur behandlung von cd1a-positivem krebs
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
EP3927744A1
(de)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
GB2597851A
(en)
|
2019-02-21 |
2022-02-09 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
GB2599227A
(en)
|
2019-02-21 |
2022-03-30 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
EP3930847B1
(de)
|
2019-02-26 |
2024-02-14 |
Inspirna, Inc. |
Anti-mertk-antikörper mit hoher affinität und ihre verwendung
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
CA3126728A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
CA3133395A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
KR20210141998A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 제조 방법
|
CA3133383A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
CN113840838A
(zh)
|
2019-03-14 |
2021-12-24 |
詹森生物科技公司 |
用于产生抗tnf抗体组合物的制造方法
|
KR20210141583A
(ko)
|
2019-03-18 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
KR20210150623A
(ko)
|
2019-03-29 |
2021-12-10 |
제넨테크, 인크. |
세포 표면 단백질 상호작용의 조절 인자 및 이와 관련된 방법 및 조성물
|
SG11202110732XA
(en)
|
2019-03-29 |
2021-10-28 |
Atarga Llc |
Anti fgf23 antibody
|
AU2020257748A1
(en)
|
2019-04-19 |
2021-11-18 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor recognizing modification site of antibody
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
US20220227853A1
(en)
|
2019-05-03 |
2022-07-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
KR20220012883A
(ko)
|
2019-05-23 |
2022-02-04 |
얀센 바이오테크 인코포레이티드 |
Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
|
CA3141531A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
MX2021014885A
(es)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica.
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
AU2020291527A1
(en)
|
2019-06-11 |
2022-01-20 |
Alector Llc |
Anti-Sortilin antibodies for use in therapy
|
BR112021025421A2
(pt)
|
2019-06-17 |
2022-02-01 |
Visterra Inc |
Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
WO2021010326A1
(ja)
|
2019-07-12 |
2021-01-21 |
中外製薬株式会社 |
抗変異型fgfr3抗体およびその使用
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
TW202118774A
(zh)
|
2019-07-26 |
2021-05-16 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
EP4003526A2
(de)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
An gprc5d bindende antikörper
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
CR20220078A
(es)
|
2019-07-31 |
2022-06-24 |
Alector Llc |
Anticuerpos anti-ms4a4a y métodos de uso de los mismos
|
FI4007777T3
(fi)
|
2019-08-02 |
2024-01-11 |
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap |
CAR-T-soluja B-solujen kypsymisantigeeniä (BCMA) vastaan multippelin myelooman hoitoon
|
KR102509648B1
(ko)
|
2019-08-06 |
2023-03-15 |
아프리노이아 테라퓨틱스 리미티드 |
병리학적 타우 종에 결합하는 항체 및 이의 용도
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
MX2022001732A
(es)
|
2019-08-12 |
2022-05-06 |
Purinomia Biotech Inc |
Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
|
US20220242962A1
(en)
|
2019-08-12 |
2022-08-04 |
Aptevo Research And Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
WO2021044014A1
(en)
|
2019-09-04 |
2021-03-11 |
Y-Biologics Inc. |
Anti-vsig4 antibody or antigen binding fragment and uses thereof
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
CA3149892A1
(en)
|
2019-09-05 |
2021-03-11 |
Eric M. Ostertag |
Allogeneic cell compositions and methods of use
|
KR20220062304A
(ko)
|
2019-09-12 |
2022-05-16 |
제넨테크, 인크. |
루푸스 신장염을 치료하는 조성물과 방법
|
CN114450024A
(zh)
|
2019-09-16 |
2022-05-06 |
表面肿瘤学公司 |
抗cd39抗体组合物和方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
EP4031580A1
(de)
|
2019-09-20 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Dosierung für anti-tryptase-antikörper
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
JP2022550067A
(ja)
|
2019-09-27 |
2022-11-30 |
ヤンセン バイオテツク,インコーポレーテツド |
抗ceacam抗体及びその使用
|
US20220281997A1
(en)
|
2019-09-27 |
2022-09-08 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH Domain Antibodies and Use Thereof
|
EP4048693A1
(de)
|
2019-09-27 |
2022-08-31 |
F. Hoffmann-La Roche AG |
Dosieren zur behandlung mit anti-tigit- und anti-pd-l1-antagonist-antikörpern
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
BR112022007216A2
(pt)
|
2019-10-18 |
2022-08-23 |
Genentech Inc |
Métodos para tratamento de linfoma difuso, kit e imunoconjugado
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
KR20220087498A
(ko)
|
2019-10-21 |
2022-06-24 |
노파르티스 아게 |
Tim-3 억제제 및 그의 용도
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
EP4055388A1
(de)
|
2019-11-06 |
2022-09-14 |
Genentech, Inc. |
Diagnostische und therapeutische verfahren zur behandlung von hämatologischem krebs
|
US20230190922A1
(en)
|
2019-11-20 |
2023-06-22 |
Bavarian Nordic A/S |
Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
IL293827A
(en)
|
2019-12-13 |
2022-08-01 |
Alector Llc |
Anti-mertko antibodies and methods of using them
|
CN114867494B9
(zh)
|
2019-12-13 |
2024-01-12 |
基因泰克公司 |
抗ly6g6d抗体及使用方法
|
MX2022007635A
(es)
|
2019-12-18 |
2022-07-19 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4.
|
US20210188971A1
(en)
|
2019-12-19 |
2021-06-24 |
Quidel Corporation |
Monoclonal antibody fusions
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
CA3162246A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
PE20221585A1
(es)
|
2019-12-27 |
2022-10-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4084821A2
(de)
|
2020-01-03 |
2022-11-09 |
Marengo Therapeutics, Inc. |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
EP4087607A1
(de)
|
2020-01-06 |
2022-11-16 |
Vaccinex, Inc. |
Anti-ccr8-antikörper und verwendungen davon
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2021142448A2
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock,Inc. |
Tgf-beta inhibitors and use thereof
|
IL294650A
(en)
|
2020-01-11 |
2022-09-01 |
Scholar Rock Inc |
Inhibitors of tgf in the cell and their use
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
WO2021144657A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3167027A1
(en)
|
2020-02-05 |
2021-08-12 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
KR20220139357A
(ko)
|
2020-02-10 |
2022-10-14 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
Cldn18.2 항체 및 그의 사용
|
CA3167349A1
(en)
|
2020-02-10 |
2021-08-19 |
Qing Zhou |
Claudin 18.2 antibody and use thereof
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
US20230192900A1
(en)
|
2020-02-13 |
2023-06-22 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
EP4103608A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispezifische antikörper gegen cd9 und cd137
|
EP4103612A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispezifische antikörper gegen cd9
|
US20230096030A1
(en)
|
2020-02-13 |
2023-03-30 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
EP4103610A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Anti-cd4-ctla4 bispezifische antikörper
|
EP4103285A2
(de)
|
2020-02-14 |
2022-12-21 |
Jounce Therapeutics, Inc. |
Antikörper und fusionsproteine, die an ccr8 binden, und deren verwendungen
|
CA3166155A1
(en)
|
2020-02-18 |
2021-08-26 |
Spencer LIANG |
Pilra antibodies and methods of use thereof
|
JP2023516941A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト、多重特異性抗体及びその使用
|
CA3169939A1
(en)
|
2020-02-28 |
2021-09-02 |
Jie Xue |
Anti-cd137 construct and use thereof
|
MX2022011050A
(es)
|
2020-03-06 |
2022-12-15 |
Ona Therapeutics S L |
Anticuerpos anti-cd36 y su uso para tratar cancer.
|
MX2022011178A
(es)
|
2020-03-10 |
2023-01-04 |
Massachusetts Inst Technology |
Composiciones y metodos para inmunoterapia contra cancer positivo para npm1c.
|
EP4118107A1
(de)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimäre stimulationsrezeptoren und verfahren zur verwendung bei der t-zell-aktivierung und -differenzierung
|
AU2021233158A1
(en)
|
2020-03-11 |
2022-09-29 |
Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol (Igtp) |
CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
|
CA3174680A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2021188749A1
(en)
|
2020-03-19 |
2021-09-23 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
PE20230414A1
(es)
|
2020-03-24 |
2023-03-07 |
Genentech Inc |
Agentes de fijacion a tie2 y metodos de uso
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
CN115397850A
(zh)
|
2020-03-30 |
2022-11-25 |
豪夫迈·罗氏有限公司 |
与vegf和pdgf-b结合的抗体及其使用方法
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
JP2023519930A
(ja)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
インフルエンザh3n2ウイルスのヘマグルチニン(ha)およびノイラミニダーゼ(na)に対するモノクローナル抗体
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック, インコーポレイテッド |
がんに対する治療方法及び診断方法
|
AU2021248643A1
(en)
|
2020-04-03 |
2022-10-27 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
EP4136459A1
(de)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
|
EP4135758A1
(de)
|
2020-04-14 |
2023-02-22 |
Poseida Therapeutics, Inc. |
Zusammensetzungen und verfahren zur verwendung bei der behandlung von krebs
|
AU2021256936A1
(en)
|
2020-04-15 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
MX2021015024A
(es)
|
2020-04-28 |
2022-01-18 |
Univ Rockefeller |
Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
|
CN115461375A
(zh)
|
2020-04-30 |
2022-12-09 |
基因泰克公司 |
Kras特异性抗体及其用途
|
EP4143236A1
(de)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Manipulierte immunglobuline
|
EP4143224A1
(de)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunglobulinvarianten
|
IL297830A
(en)
|
2020-05-03 |
2023-01-01 |
Levena Suzhou Biopharma Co Ltd |
Anti-drug compounds (adcs) comprising an anti-trop-2 antibody, compounds comprising such adcs, as well as methods for their production and use
|
WO2021226290A1
(en)
|
2020-05-05 |
2021-11-11 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
EP4153312A1
(de)
|
2020-05-17 |
2023-03-29 |
AstraZeneca UK Limited |
Sars-cov-2-antikörper und verfahren zur auswahl und verwendung davon
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
US20230220057A1
(en)
|
2020-05-27 |
2023-07-13 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
IL298735A
(en)
|
2020-06-02 |
2023-02-01 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and their uses
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
WO2021247618A1
(en)
|
2020-06-02 |
2021-12-09 |
10X Genomics, Inc. |
Enrichment of nucleic acid sequences
|
EP4161653A1
(de)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
|
BR112022024996A2
(pt)
|
2020-06-08 |
2022-12-27 |
Hoffmann La Roche |
Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
CA3181672A1
(en)
|
2020-06-18 |
2021-12-23 |
Shi Li |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
JP2023531722A
(ja)
|
2020-06-24 |
2023-07-25 |
ビステラ, インコーポレイテッド |
Aprilに対する抗体分子およびその使用
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
BR112023000839A2
(pt)
|
2020-07-17 |
2023-02-07 |
Genentech Inc |
Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo
|
PE20231565A1
(es)
|
2020-07-17 |
2023-10-04 |
Pfizer |
Anticuerpos terapeuticos y sus usos
|
BR112023000603A2
(pt)
|
2020-07-20 |
2023-01-31 |
Astrazeneca Uk Ltd |
Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos
|
KR20230040331A
(ko)
|
2020-07-21 |
2023-03-22 |
알로젠 테라퓨틱스 인코포레이티드 |
강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도
|
MX2023000888A
(es)
|
2020-07-21 |
2023-02-22 |
Genentech Inc |
Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
IL300121A
(en)
|
2020-07-29 |
2023-03-01 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
AU2021328375A1
(en)
|
2020-08-18 |
2023-04-13 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
EP4204450A2
(de)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
An calreticulin bindende multifunktionelle moleküle und verwendungen davon
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
EP4204021A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
KR20230084497A
(ko)
|
2020-09-11 |
2023-06-13 |
메디뮨 리미티드 |
치료용 b7-h4 결합 분자
|
KR20230066095A
(ko)
|
2020-09-12 |
2023-05-12 |
메디뮨 리미티드 |
항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
MX2023004436A
(es)
|
2020-10-15 |
2023-05-08 |
UCB Biopharma SRL |
Moleculas de union que multimerizan cd45.
|
EP4232040A1
(de)
|
2020-10-20 |
2023-08-30 |
F. Hoffmann-La Roche AG |
Kombinationstherapie aus pd-1-achsenbindenden antagonisten und lrrk2-inhibitoren
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022090181A1
(en)
|
2020-10-28 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
KR20230095119A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
|
EP4240758A1
(de)
|
2020-11-04 |
2023-09-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper
|
EP4240493A2
(de)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern und anti-cd79b-antikörper-wirkstoffkonjugaten
|
CA3196076A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4251647A1
(de)
|
2020-11-24 |
2023-10-04 |
Bio-Techne Corporation |
Anti-sever-antikörper des akuten atemwegssyndroms coronavirus
|
WO2022119976A1
(en)
|
2020-12-01 |
2022-06-09 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
WO2022120224A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
PE20231953A1
(es)
|
2020-12-07 |
2023-12-06 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos
|
IL303294A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
US20220213199A1
(en)
|
2020-12-17 |
2022-07-07 |
Hoffmann-La Roche Inc. |
Anti-HLA-G antibodies and use thereof
|
AU2021401316A1
(en)
|
2020-12-18 |
2023-07-06 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4271482A2
(de)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
EP4277664A1
(de)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Antikörper-pyrrolobenzodiazepinderivat-konjugat
|
CA3204731A1
(en)
|
2021-01-13 |
2022-07-21 |
John T. POIRIER |
Anti-dll3 antibody-drug conjugate
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
JP2024503506A
(ja)
|
2021-01-20 |
2024-01-25 |
ビステラ, インコーポレイテッド |
インターロイキン-2変異体およびその使用
|
EP4284510A1
(de)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
WO2022185224A1
(en)
|
2021-03-02 |
2022-09-09 |
Mark Hasleton |
Treatment and/or reduction of occurrence of migraine
|
TW202302645A
(zh)
|
2021-03-03 |
2023-01-16 |
法商皮爾法伯製藥公司 |
抗vsig4抗體或抗原結合片段及其用途
|
US20240041978A1
(en)
|
2021-03-03 |
2024-02-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
La protein as a novel regulator of osteoclastogenesis
|
EP4301418A1
(de)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antikörper-wirkstoff-konjugate mit einem anti-bcma-antikörper
|
TW202302646A
(zh)
|
2021-03-05 |
2023-01-16 |
美商當康生物科技有限公司 |
抗vista構築體及其用途
|
US20220298236A1
(en)
|
2021-03-12 |
2022-09-22 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
WO2022190034A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022195551A1
(en)
|
2021-03-18 |
2022-09-22 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
CR20230488A
(es)
|
2021-03-18 |
2023-12-12 |
Medimmune Ltd |
Moléculas de unión terapéuticas
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗tmem106b抗体
|
EP4314049A1
(de)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7-konstrukte und verwendungen davon
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
WO2022233764A1
(en)
|
2021-05-03 |
2022-11-10 |
UCB Biopharma SRL |
Antibodies
|
EP4334343A2
(de)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
|
EP4334348A1
(de)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27-antikörper und verwendungen davon
|
BR112023023622A2
(pt)
|
2021-05-12 |
2024-02-06 |
Genentech Inc |
Métodos para tratar linfoma difuso, kits, imunoconjugados, polatuzumabe vedotina e imunoconjugado para uso
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2022256313A1
(en)
|
2021-06-01 |
2022-12-08 |
10X Genomics, Inc. |
Validation of a unique molecular identifier associated with a nucleic acid sequence of interest
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
CN117480184A
(zh)
|
2021-06-04 |
2024-01-30 |
中外制药株式会社 |
抗ddr2抗体及其用途
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2022258600A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
AU2022293389A1
(en)
|
2021-06-14 |
2024-01-04 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
CA3221555A1
(en)
|
2021-06-23 |
2022-12-29 |
Kimberly LONG |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
AU2022297107A1
(en)
|
2021-06-25 |
2024-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体
|
CA3221281A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
AU2022306144A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
KR20240032991A
(ko)
|
2021-07-09 |
2024-03-12 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 생성을 위한 제조 방법
|
AU2022306973A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3226281A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
WO2023012343A1
(en)
|
2021-08-06 |
2023-02-09 |
Institut Du Cancer De Montpellier |
Methods for the treatment of cancer
|
AU2022328390A1
(en)
|
2021-08-10 |
2024-03-21 |
Adimab, Llc |
Anti-gdf15 antibodies, compositions and uses thereof
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
CA3228822A1
(en)
|
2021-08-26 |
2023-03-02 |
Jan Tkac |
Glycoprotein biomarkers for diagnosing cancer
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
CN117881784A
(zh)
|
2021-08-31 |
2024-04-12 |
大正制药株式会社 |
抗生长激素抗体
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
WO2023031881A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
CA3233506A1
(en)
|
2021-10-04 |
2023-04-13 |
Joseph S. LUCAS |
Transposon compositions and methods of use thereof
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
AR127269A1
(es)
|
2021-10-08 |
2024-01-03 |
Chugai Pharmaceutical Co Ltd |
Formulación de anticuerpo anti-hla-dq2.5
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023086824A1
(en)
|
2021-11-10 |
2023-05-19 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
US20230416361A1
(en)
|
2022-04-06 |
2023-12-28 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
US20240092921A1
(en)
|
2022-04-25 |
2024-03-21 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023250402A2
(en)
|
2022-06-22 |
2023-12-28 |
Antlera Therapeutics Inc. |
Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024062038A1
(en)
|
2022-09-21 |
2024-03-28 |
Elthera Ag |
Novel binding molecules binding to l1cam
|